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1 Summary 
This work describes the analysis of a novel, isolated, autosomal dominant form of 
Fanconi´s syndrome, a disorder of the renal proximal tubule associated with 
decreased reapsorption of solutes from the primary urine. This yet unknown 
Fanconi´s syndrome is evoked by a mutation in the third codon of the peroxisomal 
protein enoyl-CoA hydratase / L-3-hydroxyacyl-CoA dehydrogenase (EHHADH), also 
called “Fanconi-associated protein”, which results in the substitution of a glutamic 
acid residue with lysine (p.E3K). By complementing proteomic and metabolomic 
analyses of wildtype- and mutant-EHHADH-expressing proximal tubular cell lines 
(LLC-PK1) with different biochemical and cell biological investigations, the underlying 
pathomechanism is elucidated. The E3K-mutation leads to the erroneous localization 
of peroxisomal EHHADH into mitochondria causing a mitochondriopathy. Upon 
mistargeting of EHHADHMUT into mitochondria, it replaces an alpha subunit of the 
mitochondrial trifunctional protein (MTP). The MTP normally builds a heterooctamer 
consisting of four alpha and four beta subunits and is involved in mitochondrial fatty 
acid β-oxidation. The incorporation into MTP impairs both mitochondrial β-oxidation 
and respiratory supercomplex assembly, leading to a decreased oxidative 
phosphorylation capacity. Impairment of the former is shown by the characteristic 
accumulation of hydroxyacyl-, enoyl- and acylcarnitines in the cell culture 
supernatant, thus resembling the situation in patients with MTP and/or LCHAD 
deficiency. The impaired mitochondrial β-oxidation consequently decreases cellular 
long-chain fatty acid uptake and the acetyl-CoA production in EHHADHMUT cell line. 
In addition, EHHADHMUT is also incorporated into respiratory supercomplexes, 
thereby disturbing their assembly, as shown by blue native PAGE. As a result of 
impaired mitochondrial β-oxidation and diminished supercomplex assembly the 
EHHADHMUT cell line shows a decreased oxidative phosphorylation capacity and 
reduced ATP generation. This mitochondriopathy results in the decreased tubular 
reabsorption of electrolytes and low-molecular-weight proteins, leading to the 
Fanconi´s syndrome. 
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2 Zusammenfassung 
Diese Arbeit beschreibt die Analyse einer neuen Form eines isolierten, autosomal 
dominanten Fanconi Syndroms, einer Erkrankung des proximalen Tubulus der Niere, 
die mit einer verringerten Absorption verschiedener Komponenten aus dem 
Primärharn einhergeht. Dieses bisher unbekannte Fanconi Syndrom wird durch eine 
Mutation am N-terminalen Ende des peroxisomalen Proteins Enoyl-CoA Hydratase / 
L-3-Hydroxyacyl-CoA Dehydrogenase (EHHADH), auch „Fanconi-assoziertes 
Protein“ genannt, hervorgerufen. In dieser Arbeit werden proteomische und 
metabolomische Analysen einer renalen proximalen tubulären Zelllinie (LLC-PK1) 
durch verschiedene biochemische und zellbiologische Untersuchungsmethoden 
ergänzt, um den zugrundeliegenden Pathomechanismus aufzuklären. Die E3K-
Mutation führt zu einer fehlerhaften Lokalisierung von EHHADH in die Mitochondrien, 
wodurch eine Mitochondriopathie hervorgerufen wird. In den Mitochondrien wird 
EHHADHMUT ins mitochondriale trifunktionelle Protein (engl.: „mitochondrial 
trifunctional protein / MTP“) an Stelle einer alpha-Untereinheit eingebaut. Das MTP 
ist an der mitochondriellen β-Oxidation von Fettsäuren beteiligt und besteht 
normalerweise aus je vier alpha- und beta-Untereinheiten, welche ein Hetero-
Oktamer bilden. Der Einbau ins MTP beeinträchtigt dabei sowohl die mitochondriale 
β-Oxidation von Fettsäuren als auch die Zusammensetzung der Superkomplexe der 
Atmungskette. Beide Vorgänge führen zu einer verringerten Aktivität der oxidativen 
Phosphorylierung. 
Die Störung der mitochondrialen β-Oxidation wird durch die charakteristische 
Akkumulation von Hydroxyacyl-, Enoyl- und Acylcarnitinen im Zellkulturmedium 
experimentell bestätigt; damit weisen die Medien ein ähnliches Muster wie Seren von 
Patienten mit MTP- und/oder LCHAD-Defizienz auf. Die gestörte mitochondriale β-
Oxidation von Fettsäuren führt nachfolgend zu einer erniedrigten zellulären 
Aufnahme langkettiger Fettsäuren und zu einer erniedrigten Produktion von Acetyl-
CoA in der EHHADHMUT Zelllinie. Zusätzlich zu der gestörten β-Oxidation ist auch die 
Bildung von Superkomplexen der Atmungskette gestört. Aufgrund dessen sind die 
oxidative Phosphorylierung und ATP-Produktion in den betroffenen Zelllinien 
erniedrigt. Die durch die Mislokalisation entstandene Mitochondriopathie ist der 
Grund für die erniedrigte tubuläre Resorption von Glukose, Aminosäuren, Phosphat, 
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Kalium und niedermolekularen Proteinen, welche in erster Linie zu Minderwuchs und 
Vitamin-D-resistenter Rachitis führt. 
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3 Introduction 
3.1 The kidney 
The kidneys are paired, bean-shaped organs, that are located in human behind the 
retroperitoneum in the abdominal cavity, one on either side of the spine, between the 
twelfth thoracic vertebra and the third lumbar vertebra 1. They have three main 
functions: they are major excretory organs, they regulate the salt- and water balance, 
and they have an endocrine function. Each kidney contains about 0.5 – 1 million 
nephrons that are divided in cortical and juxtamedullary nephrons. Each nephron is 
composed of a glomerulus and a tubular apparatus 2. The glomerulus is located in 
the cortex of the kidney and fed with blood by the afferent arteriole, which splits into 
the glomerular capillary loops and exits through the efferent ateriole. Along the 
glomerular capillary wall the blood is filtered, by which the primary urine is produced 
into the Bowman´s space.  
 
 
Figure 1: Schematic representation of a glomerulus. 
(Figure from Avner E. D., H.W.E., Niaudet P., Yoshikawa N., Pediatric Nephrology, Springer Verlag 
Berlin Heidelberg, Sixth Edition.) 
 
Every day about 170 L of primary urine are filtered in the glomerula. The transudation 
along the capillary wall happens across three layers: the endothelial cells of the 
capillary wall with endothelial pores, the circumambient basement membrane, and 
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the glomerular epithelial cells (podocytes) with foot protrusions on the side of the 
Bowman´s space. The glomerular filtration is a permselective and pressure 
dependent process due to the hydrostatic and oncotic pressure difference between 
capillary lumen and the Bowman´s space 1. The selective permeability depends on 
both the size and the charge of molecules. Only molecules with a diameter < 4 nm 
and a molecular weight < 50 kDa are filtered across the capillary wall, and the 
basement membrane is nearly impermeable to negatively charged macromolecules 1-
3 due to its high content of negatively charged heparan sulfate. 
Subsequent to the urinary pole, the tubular apparatus arises. The main function of 
the tubular apparatus is the production of urine from the primary urine. The tubular 
apparatus is divided into different segments: proximal tubule, Henle´s loop, distal 
tubule, and the collecting duct. 
The mitochondria-rich proximal tubule is responsible for the reabsorption of nearly all 
the filtered water and solutes, approximately two thirds of the previously filtered NaCl, 
95% of the bicarbonate, and the entire glucose and amino acids 2. Characteristic for 
the proximal tubule cells is the brush-border membrane, which creates a large 
luminal surface, as well as the “leaky” tight junctions, which are permeable for small 
ions and water 3. The pars recta, the straight segment of the proximal tubule, the 
descending and ascending thin limb segment and the thick ascending limb are parts 
of the loop of Henle. The loop of Henle is responsible for the formation of an osmotic 
gradient for the urinary concentration. The pars recta shows the same transport 
systems as the proximal tubule, and the thin descending limb segment shows nearly 
no active transport, however a passive transport of cations takes place through the 
“leaky” tight junctions. The thin ascending limb segment and the thick ascending limb 
are the important parts of the loop of Henle. They show active transport of NaCl from 
the luminal to the basolateral side, while they are impermeable to water, resulting in a 
higher osmolarity in the interstitial space. Water is transported through the loop-like 
arrangement of the tubule and the higher interstitial space osmolarity from the thin 
descending limb to the interstitial space, which leads to a concentrated luminal fluid 
in the descending limb segment. In the ascending limb segment more solutes are 
transported into the interstitital space, so that the osmolarity of the tubular fluid drops. 
Thus, the tubular fluid is hypotonic at the end of the loop of Henle 2. The thick 
ascending limb comes in contact with the vas afferens of the own glomerulum at the 
end of the loop of Henle (Figure 1). To be more precise, the macula densa cells of 
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the thick ascending limb touch the extraglomerular mesangial cells and the renin 
producing juxtaglomerular cell of the vas afferens. Together, the three cell types build 
the juxtaglomerular apparatus, which regulates the function of each nephron. In case 
of an elevated blood pressure, which is accompanied with an elevated glomerular 
filtration rate (GFR), this can only partly be rescued by the autoregulation of the 
kidney. This elevated GFR leads to an increased concentration of NaCl in the 
ascending limb segment of the loop of Henle. The registered elevated NaCl 
concentration is counteracted by a constriction of the afferent arteriole, thereby 
decreasing the GFR. A decrease in NaCl concentration on the other hand, has the 
inverse effect. Subsequent to the juxtaglomerular apparatus the tubular fluid reaches 
the distal tububule ending in the collecting duct. The fine tuning of the urine occurs in 
the distal nephron segment. In contrast to the “leaky” tight junctions of the proximal 
tubulus and the loop of Henle, the tight junctions of the distal nephron are tight. The 
nadir of luminal fluid osmolality is achieved in the distal nephron, where NaCl is also 
resorbed form the luminal fluid and the membrane is impermeable to water. The urine 
has an osmolality of ~ 50 mOsm/kg water entering the collecting duct 4. The urine 
produced by the nephrons is initially collected in the renal pelvis, to be then 
transported over the ureter to the urinary bladder. 
 
3.2 Transport processes in the proximal tubulus 
The proximal tubule is the first segment of the tubular component of the nephron. It is 
responsible for the reabsorption of nearly all the filtered water and solutes. This 
means that in the proximal tubule 60% of the sodium, as well as 60% of the 
potassium, water and chloride, 95 % of the bicarbonate, and nearly all of the filtered 
glucose and amino acids are reabsorbed. For a detailed overview of the reabsorbed 
solutes and water see also Table 1. 
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Table 1: Transport of substances in the proximal tubulus segment 
2
. 
Substances Transport in the proximal tubulus in % 
Water 60 
Creatinine 0 
Sodium 60 
Chloride 55 
Potassium 60 
Bicarbonate 95 
Calcium 60 
Phosphate 70 
Magnesium 30 
Glucose 99 
Amino acids 99 
Urea 50 
 
In the proximal tubule four main transport mechanisms are at work, the primary-
active transport, the secondary-active transport, endocytosis of large molecules, and 
passive transport across the “leaky” tight junctions. These transport processes are 
shown schematically in Figure 2. 
 
3.2.1 Sodium transport 
The steep electrochemical gradient of sodium is generated by the Na+/K+-ATPase, 
which is imbedded in the basolateral membrane. The Na+/K+-ATPase exports three 
sodium ions and imports two potassium ions for every ATP consumed. It is an 
example for a primary active transport of the proximal tubular cell. This primary-active 
transport of sodium and the resulting concentration gradient is a requirement for the 
secondary-active transport of sodium on the luminal side, where it is transported into 
the cell through the Na+-coupled symporter, or the Na+/H+-antiporter. On the 
basolateral side sodium is transported out of the cell by the Na+,3HCO3
- -symporter. 
In addition to the primary- and secondary-transport of sodium, sodium is also 
passively transported into the interstitium over the “leaky” tight junctions. 
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3.2.2 Luminal Na+-coupled symporter for the transport of bicarbonate, 
glucose and amino acids 
At the luminal membrane, different Na+-coupled symporters are responsible for the 
secondary-active transport of bicarbonate, glucose and amino acids.  
Bicarbonate is produced in the proximal tubular cells by the carboanhydrase, which is 
imbedded in the luminal membrane. This bicarbonate is exported into the interstitium 
by the basolateral Na+,3HCO3
- -symporter. 
Glucose is imported into the proximal tubular cells via a luminal Na+-coupled symport. 
Two different symporters, SGLT1 and SGLT2, are responsible for the import of 
glucose at the luminal membrane. SGLT1 couples the transport of glucose and 
galactose to the transport of two sodium ions, while SGLT2 couples the transport of 
glucose to one sodium ion. SGLT1 has a higher affinity than SGLT2. In the early 
proximal tubulus 95 % of the glucose is reabsorpted by the action of SGLT2. 
Together with the action of SGLT 1 at the end of the proximal tubulus, nearly all of 
the glucose is reabsorbed.  
 
3.2.3 Protein and peptide transport 
Di - and tripeptides are reabsorbed at the luminal membrane by peptide-H+-
symporters. Peptides with disulfide bridges and proteins are reabsorbed through 
endocytosis. First, these proteins are bound to specified receptors at the luminal 
membrane. Then the protein-receptor complexes are enclosed in small vesicles that 
are invaginated from the cellular plasma membrane 5. Through the action of Na+/H+-
antiporter and H+-ATPase, protons are pumped into the protein containing vesicles. 
This leads to the dissociation of the protein-receptor complex. Finally, the vesicles 
are fused with lysosomes. The proteins are degraded to their corresponding amino 
acids and the receptors are recycled back to the luminal membrane. The resulting 
amino acids are transported through the cytosol and the basolateral membrane into 
the interstitium 2. Less than 1% of proteins and peptides remain in the primary urine. 
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3.2.4 Water and chloride transport 
Primary- and secondary active transport of solutes from the luminal fluid in the 
proximal tubular cells lead to a passive transport of water through water channels in 
the cell membrane and across the tight junctions. This transport of water drags along 
the water-solved ions such as chloride (solvent drag). In addition to the solvent drag, 
chloride is also transported through the “leaky” tight junctions. 
 
 
Figure 2: Schematic representation of the transport processes in the proximal tubular segment. 
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3.3 Fanconi´s syndrome 
The Fanconi´s syndrome is named after the swiss pediatrician Guido Fanconi (1892-
1979) and is a generalized disorder of the proximal tubule, leading to excessive 
urinary wasting of water, amino acids, glucose, electrolytes, and low-molecular-
weight proteins.  
First Abderhalden 6 described in 1903 a 21 month-old infant with cystine crystals 
infiltrated the inner organs at autopsy. Abderhalden called the disease familiar 
cystine diathesis, which is a common cause of Fanconi´s syndrome in children 7,8. In 
1924 Lignac 9 described cystinosis in three children who also presented severe 
rickets and growth retardation. Fanconi described in 1931 10 a child with glucosuria 
and albuminuria in addition to cystinosis, which are additional aspects of Fanconi´s 
syndrome. Both, Lignac and Fanconi, also described degenerative changes in the 
proximal tubules 11. Later on, De Toni 12 found hypophosphatemia to be a further 
clinical issue and Debré 13 determined also elevated levels of organic acids in urine in 
an 11-year old girl. In 1936, Fanconi 14 determined that all of the former described 
patients show similarities and described it as the nephrotic-glucosuric dwarfism with 
hypophosphatemic rickets 15,16. McCune et al 17 and Stowers and Dent 18 confirmed 
the finding of Fanconi that the amino-aciduria and the other clinical issues originated 
within the kidney 11. 
The Fanconi´s syndrome is manifested by a global disruption of sodium-coupled 
transporter systems. A low intracellular Na+ concentration is established at the 
basolateral membrane by the action of the Na+-K+-ATPase. This low intracellular 
concentration is required for the maintenance of the lumen-to-cell gradient, which 
promotes the Na+-coupled solute entry at the luminal membrane. An inhibition of the 
basolateral Na+-K+-ATPase or a decrease in the cellular ATP-ADP ratio will exert a 
tremendous influence on the reabsorption in the proximal tubule segment. In addition 
to the reabsorption of most solutes from the primary urine, the proximal tubule 
segment is also responsible for the uptake of low molecular weight proteins from the 
glomerular filtrate via receptor-mediated endocytosis. The receptors for this process 
are megalin and cubulin, which are present at the luminal membrane. Possible 
causes for proteinuria are a lack of the receptors at the luminal membrane, defective 
endocytosis, such as impaired acidification of early endosomes, and accumulation of 
toxic agents. 
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The Fanconi´s syndrome is a class of inherited or acquired diseases, or is caused by 
the action of exogenous substances.  
 
Table 2: Range of different forms of Fanconi´s syndrome 
4
. 
Inherited Acquired 
Lowe syndrom  Sjögren syndrome 
Dent-1 disease Nephrotic syndrome 
Dent-2 disease Renal transplantation 
Cystinosis Multiple Myeloma 
Fanconi-Bickel syndrome  
Idiopathic Fanconi syndrome Exogenous substances: 
Wilson disease Drugs  
Mitochondriopathies Chemical compounds 
 Heavy metals 
 
Understanding of the development of the different forms of inherited and acquired 
Fanconi´s syndrome provides important insights in proximal tubular transport.  
 
3.3.1 Inherited Fanconi´s syndrome 
Dent´s disease is a rare X-linked proximal tubulopathy with a full-blown Fanconi´s 
syndrome, but rare extrarenal symptoms except for rickets 4,19. Depending on the 
genetic cause and pattern of signs and symptoms, two forms of Dent’s disease are 
distinguished. 
Dent-1 disease is caused by mutations in the CLCN5 gene, which encodes for a 
renal specific voltage-dependent electrogenic chloride/proton antiporter. The CLC-5 
antiporter is coexpressed with the vacuolar H+-ATPase 4 and is involved in the 
acidification of early endosomes. The decreased acidification of the early endosomes 
during endocytosis leads to a diminished recycling of megalin and cubulin back to the 
luminal membrane, causing the low-molecular-weight proteinuria. In addition, patients 
with Dent-1´s disease also present with increased urinary excretion of phosphate and 
calcium, which lead to kidney stones, nephrocalcinosis and, eventually, progressive 
renal failure 20.  
Dent-2 disease is caused by mutations in the classical Lowe oculocerebrorenal 
syndrome gene, OCRL 21. Compared to classical Lowe syndrome, patients suffering 
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from Dent-2 disease present with milder extrarenal symptoms. Nephrocalcinosis is 
also seen less frequently than in Dent-1 disease 22.  
Lowe syndrome is also a rare X-linked disorder. It is characterized by a complex 
phenotype involving major abnormalities of the eyes, central nervous system and an 
incomplete renal Fanconi´s syndrome 4. The OCRL gene encodes for 
phosphatidylinositol 4,5-bisphosphate phosphatase (PIP2 5-phosphatase), which 
colocalizes in proximal tubular cells with clathrin and megalin at the luminal 
membrane 22. It interferes with the actin cytoskeleton, and is involved in the inositol 
phosphatase signaling pathway 4. The involvement of PIP2 5-phosphatase in 
endocytosis explains the similarities seen in renal involvement between Lowe 
syndrome and Dent´s disease. The decreased activity of PIP2 5-phosphatase leads 
to an accumulation of phosphatidylinositol 4,5-bisphosphate (PIP2) and actin stress 
fibres, which have an tremendous effect on epithelial function4. 
 
Mitochondriopathies are other inherited causes for Fanconi´s syndrome, as is the 
case with the Fanconi´s syndrome studied here. In proximal tubular cells, the major 
source of energy is fatty acid oxidation 23. Proximal tubular cells reabsorb solutes and 
water from the glomerular filtrate close to the cellular energy demand as Beck et al. 24 
showed an intracellular decrease in ATP after stimulation of sodium-dependent 
transport. Therefore, it is not surprising, that inherited mitochondriopathies, which are 
caused by mutation of mitochondrial or nuclear DNA encoding for functional or 
structural mitochondrial proteins, are often associated with Fanconi´s syndrome. 
 
3.3.2 Acquired Fanconi´s syndrome 
Fanconi´s syndrome can also occur secondary to certain diseases or after the 
administration of exogenous substances. The development of a Fanconi´s syndrome 
secondary to a disease is rarely seen. In patients with Sjögren syndrome, only 3 % 
manifest Fanconi´s syndrome 25. Equally uncommon is the development of a 
Fanconi´s syndrome 4 after renal transplantation. In multiple myeloma, renal 
involvement mostly manifests as proteinuria and only rarely as full-blown Fanconi´s 
syndrome 26.  
Exogenous substances such as drugs, chemicals and heavy metals, can also cause 
Fanconi´s syndrome. Drugs like valproic 27 acid, tenofovir 28, Chinese herbs 29,30 or 
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expired tetracycline 31 have been reported to cause a Fanconi´s syndrome. The 
decreased transport of proximal tubular cells after the administration of valproic acid 
originates from the fact that this drug causes respiratory chain defects and decreases 
lysosomal enzyme activity 4. The major degradation products of expired tetracycline, 
namely epitetracycline, anhydrotetracycline and 4-epianhydrotetracycline, are also 
toxic to proximal tubular cells 32. Antiviral agents, for example adefovir, which acts a 
reverse transcriptase inhibitor, interact with organic anion transporter and lead to 
mitochondrial damage and tubular toxicity. The non-specific herbicide paraquad, 
toluene and 6-mercaptopurine may also lead to Fanconi´s syndrome and renal 
failure. The kidney is the first organ of heavy metal toxicity, including lead, cadmium, 
mercury, chromium and platinum. Lead poisoning leads to the development of a 
Fanconi´s syndrome, with aminoaciduria and glucosuria which can persist for up to 
13 years 4,33. Lead thereby disrupts mitochondrial respiration, phosphorylation and 
can directly inhibit SLC3A1, which is a renal amino acid transporter for the transport 
of neutral and basic amino acids across the renal brush border 34. The threshold for 
proximal tubular injury by lead is a blood lead level of 60 µg/dL 33. Cadmium, on the 
other hand, causes Fanconi’s syndrome via production of free radicals that alter 
mitochondrial activity or induce mitochondrial gene deletion following long time 
exposure and inhibits H+-ATPase which leads to a Fanconi-like syndrome 4.  
 
3.4 Mitochondria 
The mitochondrion is a membrane bound organelle found in most eukaryotic cells. 
Mitochondria are mostly shaped like a rod. They are between 2 - 8 µm in length and 
0.2 - 1 µm in diameter 5. Especially cells with high energy-demand are rich in 
mitochondria, as seen in cardiac cells, muscle cells, cells of the central nervous 
system, sensory cells, ovocytes, sperm and cells of the proximal tubule. Furthermore, 
mitochondria are localized to specific cytoplasmic areas 35 for efficient provision of 
energy where it is needed, which is the basolateral membrane in the case of proximal 
tubule cells. The main function of mitochondria is to provide energy to the cell in the 
form of adenosine triphosphate (ATP). In mitochondria the main energy producing 
pathways are located: they include the oxidation of pyruvate, the mitochondrial fatty 
acid β-oxidation, tricarboxylic acid cycle and the oxidative phosphorylation. 
Biogenesis of mitochondria is a dynamic process, with constant mitochondrial fusion 
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and fission. When the energy demand of a cell increases, the number of 
mitochondria will be increased by mitochondrial fission. Mitochondria are inherited 
normally solely from the maternal side, however there are cases where also paternal 
mitochondria are found 36. Healthy paternal mitochondria are eliminated usually 
during embryogenesis through a process that is not well understood. Consequently, 
the mitochondria found are solely of maternal origin. The endosymbiotic theory from 
1883 postulates, that mitochondria originate from prokaryotes, which were 
incorporated into a so-called primordial cell as endosymbionts and, subsequently, 
reduced to organelles. Facts supporting this theory are that the phospholipid 
cardiolipin present in the inner mitochondrial membrane (IMM) is normally only seen 
in prokaryotes and that mitochondria have their own cyclic DNA. 
 
3.4.1 Mitochondrial structure 
Mitochondria are composed of four main components, the outer membrane, the 
intermembrane space, the inner membrane and the miochondrial matrix (Figure 3). 
The mitochondrium is separated from the cytosol by the outer mitochondrial 
membrane (OMM). The inner mitochondrial membrane (IMM) separates the 
intermembrane space from the mitochondrial matrix.  
 
 
Figure 3: Schematic illustration of the mitochondrial structure. 
 
The mitochondrial membranes are mainly composed of phosphatidyl choline, 
phosphatidyl ethanolamine, cardiolipin and phosphatidyl inositol 37. Each component 
has a specific assignment in mitochondrial function. The OMM separates the 
intermembrane space from the cytosol and is freely permeable for small proteins up 
to 5,000 Da through protein complexes called porines 38. Larger proteins, in contrast, 
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must be actively transported through the outer mitochondrial membrane by a 
transport complex called TOM (translocase of the outer membrane). The main 
function of the intermembrane space is oxidative phosphorylation. Other functions 
include the exchange of proteins, lipids, or metal ions between the matrix and the 
cytosol, the regulated initiation of apoptotic cascades, signalling pathways that 
regulate respiration and metabolic functions, and the prevention of reactive oxygen 
species produced by the respiratory chain 39. The inner mitochondiral membrane 
(IMM) separates the intermembrane space from the mitochondrial matrix. The IMM is 
extensively folded in so-called cristae to increase its surface area, which is about five 
times as large as that of the OMM. The IMM is responsible for the import of proteins, 
lipids and other important metabolites into the mitochondrial matrix. In contrast to the 
OMM, it is completely impermeable, so that everything has to be transported actively. 
The impermeability is also a requirement for the maintenance of the proton gradient 
(∆pH) and membrane potential (∆ψ), which are a requirement for the electrochemical 
gradient (∆μH+). The mitochondrial matrix contains the cyclic double-stranded DNA 
and the whole machinery needed for the transcription and translation of the 
mitochondrial-encoded proteins. In addition, the enzymes for the important energy 
generating pathways are localized in the mitochondrial matrix or the IMM. 
 
3.4.2 Mitochondrial energy metabolism 
 
In mitochondria the main energy generating pathways are located, oxidation of 
pyruvate to acetyl-CoA, tricarboxylic acid cycle (TCA) cycle, mitochondrial fatty acid 
β-oxidation and oxidative phosphorylation. Mitochondria are also important for the 
controlling of the cellular redox state, Ca2+ homeostasis and apoptosis 40. 
 
Oxidation of pyruvate 
Pyruvate generated in glycolysis is transported into the mitochondria by the 
mitochondrial pyruvate carrier (MPC). In the mitochondrial matrix, pyruvate is 
irreversibly decarboxylated by the action of the pyruvate dehydrogenase complex to 
form acetyl-CoA, which enters the tricarboxylic acid cylce. Cofactors of this reaction 
are thiamine pyrophosphate, coenzyme A, α-lipoic acid, FAD, and NAD+. This 
reaction links glycoylsis and the TCA cylce.  
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Tricarboxylic acid cycle 
Enzymes of the TCA cycle are located in the mitochondrial matrix. In the first step of 
the TCA cycle, acetyl-CoA generated by the decarboxylation of pyruvate or the ß-
oxidation of even-numbered saturated fatty acids reacts with oxaloacetate to from 
citrate. Citrate is transformed into isocitrate by isomerisation. In two subsequent 
oxidative decarboxylation reactions, first α-ketoglutarate and then succinyl-CoA are 
formed, with each reaction yielding NADH and H+. Through the reaction of succinyl-
CoA to succinate, the high phosphate transfer potential compound GTP is formed. 
Succinate is then FAD-dependent oxidized to fumarate, and through the addition of 
water malate is formed. In the last step, malate is oxidized to oxaloacetate in a 
reaction catalyzed by malate dehydrogenase, which also yields NADH and H+. 
Oxalacetate reacts again with acetyl-CoA, providing citrate for another round of the 
TCA cycle.  
 
The net reaction is: 
 acetyl-CoA + 3 NAD+ + FAD + GDP+ Pi + 2 H2O 
 → 2 CO2 + CoA + 3 NADH
 + 3H+ + FADH2 + GTP 
The reducing equivalents NADH and FADH2 directly enter oxidative phosphorylation.  
 
Mitochondrial fatty acid β-oxidation 
For mitochondrial β-oxidation, fatty acids are activated in the cytosol, generating 
membrane-impermeable acyl-CoAs, which are subsequently transported into the 
mitochondrial matrix by the carnitine carrier system, which is schematically depicted 
in Figure 4. Upon release into the mitochondrial matrix, the acyl-CoAs are broken 
down to generate acetyl-CoA, which enters the TCA cycle, and NADH and FADH2, 
which are used by the electron transport chain. 
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Figure 4: Scheme of the carnitine carrier system and subsequent fatty acid β-oxidation. The 
activated long-chain fatty acids (LCFA-CoA) are transported by the carnitine carrier system, which 
consists of the CPT1, CACT and CPT2, into the mitochondrial matrix. The LCFA-CoA are converted 
into their corresponding acylcarnitines by the CPT 1, transported across the IMM by CACT and, 
ultimately, reconverted into the activated long-chain fatty acids by CPT2. In the mitochondrial matrix, 
the LCFA-CoA subsequently undergoes the first round in the β-oxidation spiral. Chain shortening of 
LCFA-CoAs takes place by the repeated action of four enzymatic reactions, oxidation of an acyl-CoA 
by the acyl-CoA dehydrogenase (AD) with flavin adenine dinucleotide (FAD) as cofactor, hydration of 
enoyl-CoA by the enoyl-CoA hydratase, a second oxidation step using the cofactor nicotineamide 
adenine dinucleotide (NAD
+
) and in the end a thiolytic cleavage by 3-keto-thiolase. 
(Illustration taken from Sim, K.G:, Hammond, J., Wilcken, B. Strategies for the diagnosis of 
mitochondrial fatty acid beta-oxidation disorders. Clin Chim Acta 2002; 323:37-58) 
 
Long-chain fatty acids represent the majority of the dietary fat undergoing ß-oxidation 
41. The latter plays an essential role in the energy metabolism of proximal tubular 
cells, which derive almost their entire energy from β-oxidation of mostly long-chain 
fatty acids 42. The enzymes of mitochondrial fatty acid β-oxidation are located at the 
inner face of the inner mitochondrial membrane as well as are distributed in the 
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mitochondrial matrix 43. Chain shortening of long-chain fatty acids takes place by the 
repeated action of four enzymatic reactions (Figure 4). 
In the first reaction, an acyl-CoA is oxidized to a trans-2,3-enoyl-CoA by acyl-CoA 
dehydrogenases (ACADs). This reaction produces a FADH2, which directly enters the 
oxidative phosphorylation at the electron transfer flavoprotein (ETF). The electrons 
form FADH2 are transferred to ETF, the reduced ETF is then oxidized by the 
ETF:ubiquinone oxidoreductase transferring the electrons to ubiquinone, which is 
then reduced to ubiquinol. By the action of complex II of the respiratory chain 
ubiquinol is reoxidized to ubiquinone. 
The second enzyme of the β-oxidation spiral is enoyl-CoA-hydratase, which forms L-
3-hydroxyacyl-CoA by the addition of water to the double bond. The hydroxy-group is 
in the next step NAD+-dependent oxidized to the corresponding ketoacyl-CoA. The 
reducing equivalent NADH is oxidized by the respiratory chain complex I.  
In the last step of the β-oxidation, which is catalyzed by keto-thiolase, the terminal 
acetyl-CoA is cleaved off to yield an acyl-CoA shortenend by two carbon atoms. The 
cleaved acetyl-CoA can then enter into the TCA and electron transport chain (ETC).  
In fatty acid β-oxidation, fatty acids are with each round shortened by two carbon 
atoms, which are released as acetyl-CoA, until the entire fatty acid is cleaved into 
acetyl-CoAs. The complete oxidation of palmitate yields 8 acetyl-CoA, 7 FADH2, 7 
NADH, yielding in total 106 ATP molecules 44.  
In mitochondria, several enzymes are present for the different steps of β-oxidation, 
which vary in their chain-length specificity. For the acyl-CoA dehydrogenase (ACAD) 
four enzymes with overlapping chain-length specificity are known: short-chain acyl-
CoA dehydrogenase (SCAD) for C4 and C6 fatty acids, medium-chain acyl-CoA 
dehydrogenase (MCAD) with high specificity for fatty acids of a chain length of C4 to 
C12, long-chain acyl-CoA dehydrogenase (LCAD) C8 to C20 fatty acids, which is 
important for unsaturated fatty acids, and very-long-chain acyl-CoA dehydrogenase 
(VLCAD) for fatty acids with a chain-length between C12 and C24 43. Of the known 
short-, medium- and long-chain keto-thiolases, only the latter two are important for β-
oxidation 43. Four subunits each of the long-chain enoyl-CoA hydratase / long-chain 
L-3-hydroxyacyl-CoA dehydrogenase (alpha-subunit) and the long-chain ketothiolase 
(beta-subunit) are assembled in the hetero-octameric mitochondrial trifunctional 
protein (MTP), which is bound to the inner face of the inner mitochondrial membrane.  
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Oxidative phosphorylation 
Glycolysis, fatty acid β-oxidation, TCA cycle and the oxidative phosphorylation are 
tightly coupled processes, as reducing equivalents produced by glycolysis, β-
oxidation and TCA cycle directly enter the oxidative phosphorylation. Oxidative 
phosphorylation is the main source for ATP production. The electrons from the 
reducing equivalents are transferred onto the respiratory complexes, and are used to 
reduce molecular oxygen together with protons from the mitochondrial matrix to 
water. In parallel protons are pumped from the matrix into the intermembrane space, 
leading to the formation of a pH-gradient and a membrane potential (voltage 
gradient). Both, the pH-gradient and the membrane potential, build up the 
electrochemical proton gradient 38. The respiratory complex V (ATP synthase) drives 
protons back into the mitochondrial matrix by the electochemical gradient, which as a 
result generates ATP from ADP. The respiratory chain complexes, complex I - IV, the 
ATP synthase (complex V), and the adenine nucleotide translocase (ANT) are 
embedded in the IMM. The complete oxidation of glucose yields 30 ATP molecules, 
from which alone 26 ATP molecules are generated by oxidative phosphorylation. The 
complete oxidation of palmitate yields 106 ATP molecules through oxidative 
phosphorylation 44. Four enzyme complexes are responsible for the electron flow and 
at the end for the reduction of oxygen to water. 
 
NADH:ubiquinone-reductase (complex I) 
Complex I is the biggest respiratory chain complex and consists of 44 subunits 45. It 
needs the flavoprotein FMN and Fe-S-cluster as prosthetic groups. It is localized in 
the inner mitochondrial membrane in an L-shaped form, where the horizontal arm lies 
in the inner mitochondrial membrane and the vertical arm protrudes into the 
mitochondrial matrix. Complex I oxidizes NADH to NAD+. The reaction leads in 
parallel to the pumping of four H+ out of the mitochondrial matrix.  
 
The net reaction is: 
NADH/H+ + ubiquinone + 4 H+matrix → NAD
+ + ubiquinole + 4 H+intermembrane 
 
Succinate:ubiquinone reductase (Complex II): 
Complex II is the smallest of the four respiratory complexes and consists of four 
subunits and equals the succinate dehydrogenase acting in the tricarboxylic acid 
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cylce. Succinate dehydrogease catalyzes the oxidation of succinate to fumarate, with 
the formation of a FADH2. Complex II does not pump protons out of the mitochondrial 
matrix.  
 
The net reaction is: 
Succinate + ubiquinone → Fumarate + ubiquinole 
 
During mitochondrial β-oxidation also FADH2 is formed. These electrons are not 
transferred onto complex II, but onto the electron transfer flavoprotein (ETF), which is 
reoxidized by the action of ETF:ubiquinone oxidoreductase. The electrons are 
transferred onto complex III. 
 
Ubiquinole:cytochrome c reductase (complex III): 
Complex III consists of 10 subunits and contains as electron carrier cytochrome b, 
cytochrome c1 and one Fe-S-cluster 46. Through the transfer of the electrons from 
ubiquinole to cytochrom c, ubiquinone is reoxidized. The mechanism of the transfer 
of electrons from ubiquinole to cytochrome c and the coupled transport of protons, is 
also called the Q cycle 44. Thereby, in total four protons are pumped into the 
intermembrane space. 
 
The net reaction is: 
ubiquinole + 2 cyt cox + 2 H
+
matrix → ubiquinone + 2 cyt cred + 4 H
+
intermembrane 
 
Cytochrome c oxidase (complex IV): 
Complex IV consists of 19 subunits and is the final proton pumping complex of the 
respiratory chain. It catalyzes the electron transport from cytochrome c to elemental 
oxygen (O2). For electron transport, complex IV contains the prosthetic groups 
cytochrome a, cytochrome a3 and two copper centers. The electron is transferred 
from cytochrome c to the first copper centre (CuA), and via cytochrome a and 
cytochrome a3 to the second copper centre (CuB). Four molecules of cytochrome c 
are bound successively to complex IV. In the end, four electrons are transferred onto 
one molecule O2, which is then completely reduced to water. In parallel, four protons 
are pumped into the intermembrane space.  
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The net reaction is: 
4 Cyt cred + 8 H
+
Matrix + O2 → 4 Cyt cox + 2 H20 + 4 H
+
intermembrane 
 
Through the complexes I, III, and IV protons are pumped from the matrix into the 
intermembrane space, leading to the formation of the electrochemical proton gradient 
that drives ATP synthesis. 
 
ATP synthase (complex V): 
The ATP synthase consists of 19 subunits, which build two main units, the FO-unit, 
which forms a proton channel across the inner mitochondrial membrane and the F1-
unit, which constitutes the catalytic unit of complex V. Protons flow through the FO-
unit down the electrochemical gradient back into the mitochondrial matrix and the F1-
unit catalyzes the reaction from ADP and organic phosphate to ATP. The function of 
the proton backflow is not the synthesis of ATP, but the release of ATP from the 
synthase 44. The mechanism of the ATP synthesis with the F1-unit is a binding-
change mechanism, with three successive steps: the binding of ADP and organic 
phoshate, the synthesis of ATP and the release of the synthesized ATP from the F1-
unit 44. The rotation of the γ-subunit of the F1-unit drives these three steps into each 
other and is required for the release of the ATP from the F1-unit. The rotation of the γ-
subunit coheres with the rotation caused by the c-subunit of the FO-unit, through the 
binding of proton from the proton-rich intermembrane space. The FO-unit consists of 
10 c-subunits and with every binding of a proton to the c-subunit, the subunits are 
rotated one step further. The c-subunit is firmly connected to the γ-subunit, so the 
active rotation of the c-subunit also rotates the γ-subunit. With each 360° rotation of 
the c-units, the γ-subunit comes to a full rotation, which correlates to the binding of 10 
protons and leads to the synthesis and release of 3 ATP molecules 44. 
 
The net reaction is: 
ADP3- + HPO4
2- + 3 H+intermembrane → ATP
4- + H20 + 2 H
+
matrix 
 
Respiratory chain supercomplexes: 
The organization of the respiratory chain complexes within the IMM has been the 
subject of intense debate 47-52. The first proposed model was the “solid state model”, 
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which suggested the arrangement of the respiratory chain complexes in an orderly 
sequence within the IMM 48. This model was soon replaced by the “liquid state 
model”, which hypothesized that the individual respiratoy chain complexes diffuse 
freely and are randomly distributed within the lipid bilayer 47,49. Today, based on the 
ovservations made by Bruet et al. 53, Boumans et al. 54 and Schägger et al. 55 in yeast 
S. cerevisiae and bovine it is believed that the respiratory chain complexes are 
organized into supercomplexes 52. The two major supercomplexes in human 
mitochondria are I1III2 and I1III2IV1 
56.  
 
3.4.3 Mitochondrial protein import 
Of the approximately 1,500 57 mitochondrial proteins, only 13 are mitochondrially 
encoded. The remainder is encoded in the nucleus and imported into mitochondria 
during or after synthesis. These proteins are synthesized as preproteins and may 
feature either an N-terminal mitochondrial targeting sequence, also called 
presequence, which is cleaved post-import, or multiple internal mitochondrial 
targeting sequences. Mitochondrial matrix proteins feature the N-terminal targeting 
sequences, whereas hydrophobic proteins, which are implemented in the IMM, 
feature multiple internal targeting signals. In contrast to peroxisomal targeting 
sequences, mitochondrial targeting sequences do not have a known amino acid 
sequence, so the import machinery recognizes many different forms of different 
targeting sequences. The N-terminal presequence of proteins consists of about 20 – 
40 amino acids residues, dotted with some positively charged amino acids (lysine, 
histidine or arginine) 58. It is suggested that the presequence forms an amphipathic α-
helix, with the positively charged amino acids lying on one side of the helix and the 
hydrophobic amino acids on the other, albeit the latter are not essential for 
mitochondrial targeting 58. Hydrophobic proteins do not contain a cleavable N-
terminal targeting sequence, but rather contain multiple internal targeting sequences, 
which are spread over the whole length of the protein. Three major translocase 
complexes are involved in the import of mitochondrial proteins, one located in the 
outer mitochondrial membrane, called translocase of the outer membrane (TOM) and 
two translocases in the inner mitochondrial membrane, called translocases of the 
inner mitochondrial membrane (TIMs), one for the import of matrix proteins (TIM23) 
and the other is responsible for the insertion of complexes in the inner membrane 
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(TIM22). The proteins are transported in an unfolded, linear state or a loop formation 
through the mitochondrial membranes, and the transport is driven by the membrane 
potential (∆ψ), which is built across the inner mitochondrial membrane and the ATP 
hydrolysis-driven action of the mitochondrial heat shock protein 70 (mtHsp70) 59.  
 
Import of proteins with an N-terminal presequence: 
For the import of proteins with a cleavable presequence, the proteins are first located 
to the OMM, where the presequence is first recognized by TOM20, then transferred 
to TOM22, TOM5 and translocated in a linear, unfolded state across OMM by the 
general import pore (GIP), which is formed by the pore-building protein TOM40. The 
translocation across the OMM is illustrated in Figure 5. In the intermembrane space, 
the preprotein is bound to the C-terminal end of TOM22 before further transport. The 
TIM23 protein exposes a domain into the intermembrane space to which the 
preprotein is bound after the translocation through the OMM. The membrane 
potential activates the channel formed by the TIM23 complex and exerts and 
electrophoretic effect on the positively charged presequence, which leads to the 
transport of the preprotein across the IMM. In the matrix, mtHsp70 binds to the 
unfolded preprotein in transit and drives the preprotein into the matrix, by the 
hydrolysis of ATP. The import of preproteins across the IMM is therefore driven by 
these two energy sources, the mitochondrial membrane potential (∆ψ) and the ATP 
hydrolysis-driven action of mtHsp70. In the matrix a mitochondrial processing 
peptidase removes the presequence and the mature matrix protein is folded. The 
heterodimeric mitochondrial processing peptidase (MPP) removes the N-terminal 
presequence proteolytically 59. The process of translocation across the IMM and the 
processing in the matrix are shown in Figure 5.  
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Figure 5: Mitochondrial protein import. 
(Figure from Pfanner, N., Wiedemann, N. Mitochondrial protein import two membranes, three 
translocases. Current opinion in cell biology 2002; 14: 400-11) 
 
Import of proteins with an internal targeting sequence: 
Hydrophobic proteins, which feature internal targeting sequences are guided during 
their transport to the OMM by chaperons to prevent misfolding and aggregation in the 
aqueous environment. After their transport to the OMM, the internal targeting 
sequences are recognized by TOM70, which in an ATP-dependent manner 
transports the preprotein to TOM22 and TOM5, before the preprotein is translocated 
across the OMM by the GIP in a loop formation (Figure 5). Subsequent to the 
translocation across the OMM, the protein binds to the TIM9-TIM10-complex in a 
loop formation, which has chaperone-like characteristics, to prevent the aggregation 
and misfolding of proteins with internal targeting sequences. The TIM9-TIM10 
complex then transports the protein across the intermembrane space to the IMM and 
binds to the TIM22 complex. The subsequent import of the protein into the IMM is 
carried out by the TIM22 complex, consisting of TIM22, TIM54 and TIM18, which is 
activated by the presence of a targeting signal. The mitochondrial membrane 
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potential (∆ψ) is the only energy source during this process. The schematic 
illustration of the transport and insertion at the IMM is shown in Figure 5. 
 
3.5 Peroxisomes 
3.5.1 Structure and Function 
Peroxisomes are small spherical organelles, which are between 0.1 - 1 µm in 
diameter and are surrounded by a single membrane 60. Peroxisomes are present in 
all eukaryotic cells and compared with mitochondria do not contain DNA or 
ribosomes, i.e., all peroxisomal proteins are encoded in the nucleus and have to be 
transported into the peroxisomes. Rhodin was the first to describe peroxisomes in 
1954. He termed them microbodies 61, and later on the term peroxisome was used. 
Peroxisomes and mitochondria are replicated by the fission of already present 
peroxisomes or mitochondria, respectively. The important functions of peroxisomes 
are oxidation and detoxification metabolism, synthesis of plasmalogen and oxidation 
of fatty acids via α- and β-oxidation.  
 
Oxidation fatty acids via α- and β-oxidation: 
In plants cells, yeast and most fungal cells β-oxidation of fatty acids take place only in 
peroxisomes, whereas in mammalian cell the β-oxidation of fatty acids take place in 
both mitochondria and peroxisomes. Peroxisomes and mitochondria both have their 
own sets of enzymes for fatty acid β-oxidation, where peroxisomes are responsible 
for the shortening of very-long-chain fatty acids, medium- and long-chain dicarboxylic 
acids, bile acid precursors, branched chain fatty acids, prostaglandins, leukotrienes, 
xenobiotics and certain mono- and polyunsaturated fatty acids 40,62 and mitochondria 
are responsible for the oxidation of short-, medium- and long-chain fatty acids. The 
shortened fatty acids acyl-CoAs from the peroxisomes are exported to the 
mitochondria for complete oxidation, because the mitochondrial fatty acid β-oxidation 
is more efficient concerning energy generation. The enzymes for peroxisomal β-
oxidation are distributed within the peroxisomal matrix. Only saturated very-long-
chain fatty acids and 2-methyl-branched fatty acids can be directly activated and are 
available for peroxisomal β-oxidation. All other fatty acids have to be converted via 
different peroxisomal enzymes into suitable substrates for peroxisomal β-oxidation 
(Figure 6). 
38 
 
 
 
 
Figure 6: Enzymatic conversion of different fatty acids to their corresponding acyl-CoA, before 
the oxidation via peroxisomal β-oxidation. 
(Figure from Wanders, R.J. Waterham, H.R. Biochemistry of mammalian peroxisomes revisited. Annu 
Rev Biochem 2008; 75: 295-332.) 
 
After the transport of the activated acyl-CoAs across the peroxisomal membrane or 
the conversion into suitable substrates, the acyl-CoA chain is shortened by the 
repeated action of four enzymatic reactions (Figure 7). The first reaction is an 
oxidation by an acyl-CoA oxidase (ACOX) to form enoyl-CoA and H2O2, hydration of 
the double bond by the action of enoyl-CoA hydratase to from 3-hydroxyacyl-CoA, 
again an oxidation to from 3-ketoacyl-CoA and NADH and H+ by the action of 3-
hydroxyacyl-CoA dehydrogenase and in the last step the thiolytic cleavage of 3 
ketoacyl-CoA to form an acetyl-CoA and an acyl-CoA chain shortened by two 
carbons. As in peroxisomes the electrons from FAD+, which is bound to the ACOX, 
cannot be passed directly into respiratory chain, the electrons are directly transferred 
onto O2 to from H2O2, and the chemical energy dissipated as heat by the action of 
catalase. The second and the third reaction of peroxisomal β-oxidation is catalyzed 
by a bifunctional protein, where in peroxisomes two types of bifunctional enzymes are 
present, the L-bifunctional enzyme and the D-bifunctional enzyme. The L-bifunctional 
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enyzme, also called EHHADH, forms and dehydrates L-3-hydroxyacyl-CoA, whereas 
the D-bifunctional enzyme forms and dehydrates D-3-hydroxyacyl-CoA 62.  
 
 
Figure 7: Schematic representation of peroxisomal β-oxidation. 
(Figure from Wanders, R.J. Waterham, H.R. Biochemistry of mammalian peroxisomes revisited. Annu 
Rev Biochem 2008; 75: 295-332.) 
 
The D-bifunctional enyzme is the main enzyme involved in the oxidation of 
polyunsaturated fatty acid and branched-chain fatty acids, whereas L-bifunctional 
enzyme (EHHADH) is mainly involved in the oxidation of straight-chain enyl-CoAs 62. 
EHHADH features the enzymatic acitivities of enoyl-CoA hydratase and L-3-
hydroxyacyl-CoA dehydrogenase. As already mentioned, the acyl-CoAs are not 
completely oxidized in peroxisomes, but shortened and subsequently transported 
over the peroxisomal carnitine acyltransferase as acylcarnitines into the mitochondria 
for complete oxidation. 
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Peroxisomal α-oxidation of fatty acids takes place whenever the Cβ is blocked by a 
methyl group and cannot be oxidized by β-oxidation. The fatty acid is then oxidized 
by α-oxidation (Figure 8), until the methyl-group no longer blocks the Cβ. The main 
substrate for α-oxidation is phytanic acid and after the first round the resulting 
pristanic acid is further oxidized by peroxisomal β-oxidation. First of all, phytanic acid 
is activated to the corresponding phytanoyl-CoA by an acyl-CoA synthase. The three 
steps from phytanoyl-CoA to pristanic acid are catalyzed by the enzymes phytanoyl-
CoA 2-hydroxylase, 2-OH-phytanoyl-CoA lyase and pristanal dehydrogenase. 
 
 
Figure 8: Peroxisomal α-oxidation of phytanic acid. 
(Figure from Wanders, R.J. Waterham, H.R. Biochemistry of mammalian peroxisomes revisited. Annu 
Rev Biochem 2008; 75: 295-332.) 
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3.5.2 Peroxisomal protein import 
As peroxisomes do not contain their own DNA, all proteins are encoded in the 
nucleus and are subsequently imported into the peroxisomes. The import of proteins 
into the peroxisomal matrix differs from the that of other organelles such as 
mitochondria or chloroplasts, as peroxisomes are capable of importing both fully 
folded and oligomeric proteins 60. A schematic representation of peroxisomal protein 
import is shown in Figure 9. Peroxisomal proteins are synthesized with either 
peroxisomal targeting sequence type 1 (PTS1) or type 2 (PTS2). The majority of 
peroxisomal proteins carries the PTS1, a C-terminal tripeptide with the sequence 
SKL or variants thereof in the form of (S/A/C)-(K/R/H)-(L/A) 60. A smaller number of 
proteins feature carries either in addition to PTS1 or solely the PTS2, which is a 
nona-peptide located within the first 20 amino acids of the N-terminus and exhibits a 
sequence of the type (R/K)-(L/V/I/Q)-XX-(L/V/I/H/Q)-(L/S/G/A/K)-X-(H/Q)-(L/A/F) 60. 
As the majority of peroxisomal matrix proteins feature a PTS1 sequence, in the 
following only the import pathway of proteins featuring a PTS1 targeting sequence is 
described in detail.  
 
 
Figure 9: Schematic figure of peroxisomal protein import. 
(Figure from Liu, S., Ma, C., Subramani, S., Recent advances in peroxisomal matrix protein import. 
Current opinion in cell biology 2012; 24: 484-9.) 
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The import of peroxisomal proteins can be divided into five steps, first the recognition 
of the peroxisomal protein by the receptor in the cytosol, the docking of the receptor-
protein complex at the peroxisomal membrane, the subsequent translocation of the 
complex through the peroxisomal membrane, the release of the protein into the 
peroxisomal matrix and in the last step the recycling of the receptor. The receptor 
responsible for the recognition of the PTS1 is called Pex5p. Upon docking, the 
receptor-protein complex is translocated to the peroxisomal membrane, where it 
interacts with the docking complex composed of Pex13p and Pex14p, where Pex14p 
is the initial binding partner of the protein-receptor-complex 60. The mechanism by 
which fully folded and oligomeric proteins are translocated across the peroxisomal 
membrane is not well understood, but over the last few years the model of a transient 
opened import pore has been favoured 60. In the peroxisomal matrix the receptor and 
protein are dissociated and, afterwards, the receptor is recycled and a subset of 
imported proteins is processed by the peroxisomal protease Tysnd1. The receptor is 
at the peroxisomal membrane ubiquitinilated, which occurs at the N-terminal end at a 
conserved cysteine residue (C11), before the export. Before the next round of import 
and export, the ubiquitinated receptor must be deubiquitinated in the cytosol, by the 
action of USP9X, an ubiquitin hydrolase. The translocation of the receptor-protein 
complex across the peroxisomal membrane and the export of the ubiquitinated 
receptor are coupled by the so-called export-driven-import model. This means, that 
the persence of an ATP hydrolysis-driven export of the ubiquitinated receptor is a 
requirement for the import of the receptor-protein complex.  
 
3.6 Enoyl-coenzyme A hydratase / L-3-hydroxyacyl-coenzyme A 
dehydrogenase (EHHADH) 
The gene EHHADH is localized on the chromosome 3q26.3 – 3q28. The cDNA 
sequence extends over 3779 nucleotides 63 and encodes for the peroxisomal protein 
Enoyl-CoA hydratase / L-3-hydroxyacyl-CoA dehydrogenase (EHHADH). EHHADH 
gene expression is the highest in liver and kidney 63. The C-terminal end of the 
protein features the typical peroxisomal targeting sequence SKL. Hence, EHHADH is 
exclusively localized in the peroxisomal matrix. EHHADH is imported without further 
processing and features a molecular weight of 79 kDa and a pI of 9.8 64. EHHADH is 
involved in peroxisomal fatty acid β-oxidation, catalyzing the second and third step, 
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namely hydration and NAD+-dependent dehydrogenation. Therefore, it is also called 
peroxisomal L-bifunctional protein. Hydration and NAD+-dependent dehydrogenation 
can also be catalyzed by the D-bifunctional protein Hsd17b4. Qi et al. 65 showed that 
the existence of a knockout mouse of EHHADH-/-, did not lead to a phenotype and 
changes in lipid metabolism, which further support the fact, that Hsd17b4 can handle 
all peroxisomal substrates. As opposed to this, Houten et al. 66 reported recently that 
EHHADH is essential for peroxisomal ß-oxidation of long-chain dicarboxylic acid 
(DCAs) to medium-chain DCAs such as adipic (C6-DCA) and suberic acid (C8-DCA). 
Houten et al. could clearly show that the formation of long-chain DCAs are disturbed 
in EHHADH-/- knockout mouse after fasting and thereby demonstrate that EHHADH 
plays an essential role in the formation of fasting-induced medium-chain DCAs and 
their carnitine esters66. In addition, it is also shown that Hsd17b4 could not 
compensate for this EHHADH deficiency. 
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4  Aim of this work 
The causes for development of renal Fanconi´s syndromes are diverse, and the renal 
Fanconi´s syndrome is still subject of intense research with all it is different inherited 
and acquired forms. 
Recently, Kleta and coworkers 67 identified a novel form of an isolated autosomal 
dominant renal Fanconi´s syndrome in an extended family with eleven affected 
members. The causative mutation was mapped to chromosome 3q27 with an LOD 
> 3 via multipoint parametric linkage analysis, with the haplotype shared by all 
affected family members, whereas it was not found in any of the unaffected family 
members. The respective gene encodes for the peroxisomal protein EHHADH 
(Enoyl-CoA hydratase/3-Hydroxyacyl-CoA dehydrogenase), which is involved in β-
oxidation of very long-chain fatty acids. The C-terminus of the protein features the 
typical peroxisomal targeting sequence SKL. Upon mutation, a negatively charged 
glutamic acid residue is exchanged for a positively charged lysine in the very N-
terminus, leading to the heterozygous missense mutation p.E3K. As knock-out mice 
(L-EHHADH-/-) did not show a phenotype, this mutation of EHHADH shows a 
dominant negative effect and leads to the monogenic disorder of Fanconi´s 
syndrome. The primary aim of this study is the elucidation of the molecular 
consequences caused by EHHADH mutation, thus facilitating the analysis of the 
respective pathomechanism. 
The working hypothesis is that mistargeting of EHHADHMUT into mitochondria upon 
mutation leads to an interference of EHHADHMUT with members of the mitochondrial 
energy metabolism. This impairment leads to the development of a 
mitochondriopathy causing diminished energy supply, which in turn causes the 
observed Fanconi´s syndrome 
I will investigate the impact of the EHHADH mutation in LLC-PK1 cells, a cell line of 
proximal tubule cells of porcine origin, which have been transfected with either 
inducible EHHADHWT or EHHADHMUT using the TetOn-system. In a first step, it has 
to be shown that mistargeting of EHHADH into mitochondria indeed occurs upon 
mutation. Subsequently, possible interaction partners of EHHADHMUT will be 
identified by co-immunoprecipitation against EHHADH from isolated mitochondria. 
Additionally, quantitative differential proteome analyses will be accomplished. The 
results will give a first hint on possible impaired energy metabolism pathways. These 
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analyses will be complemented by metabolomic measurements of the metabolic state 
of the cells to show diminished energy supply within the cells and verify the reduced 
throughput in the affected pathways identified by the proteomic analyses 
Furthermore, functional analyses will be used to determine the impact of 
EHHADHMUT on mitochondrial energy production in more detail. Thereby, I aim to 
elucidate the underlying molecular mechanisms of this novel Fanconi´s syndrome. 
 
5 Materials and Methods 
5.1 Material 
5.1.1 Cell line 
The porcine kidney proximal tubule cell line LLC-PK1 was used for all cell 
experiments. This cell line had been transfected stably by our cooperation partner R. 
Kleta at the University College London with either EHHADHWT or EHHADHMUT cDNA 
using the inducible Tet-on gene expression system. The LLC-PK1 cell line is an 
adherent cell line.  
 
5.1.2 Media 
Routine cell culture medium: 500 mL Memα + 10 % FCS (heat-inactivated) + 
2 mM L-glutamine, 1 mM sodium pyruvate + 
0.5% penicillin/streptomycin 
Stimulation medium 1: 500 mL RPMi 1640 (without glucose) + 10 % FCS 
(heat inactivated) + 2 mM L-glutamine + 
0.5% penicillin/streptomycin + 5 mM caproic acid 
Stimulation medium 2: 500 mL RPMI 1640 (without glucose) + 10 % FCS 
(heat inactivated) + 2 mM L-glutamine + 
0.5% penicillin/streptomycin + 0.5 mM L-carnitine + 
0.3 mM palmitic acid bound to BSA 
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5.1.3 Buffers and Solutions 
5.1.3.1 Cell culture 
Mitochondria isolation buffer 250 mM Sucrose, 1 mM EDTA, 10 mM MOPS, 
pH 7.2 
Ringer solution 5 mM HEPES, 1.45 M NaCl, 1.6 mM K2HPO4, 
0.4 mM KH2PO4, 5 mM glucose, 1 mM MgCl2, 
1.3 mM CaCl2,  pH 7.4 
5.1.3.2 Two-dimensional gel electrophoresis 
Acrylamide gel (10%) 16.5 mL Acrylamide solution 30 % (37.5:1), 12.5 
mL 1.5 M Tris- HCl pH 8.8, 0.5 mL 10 % SDS 
solution, 0.5 mL 10 % APS solution, 0.085 mL 
10 % TEMED solution, 20 mL A. bidest. 
Agarose solution 0.5 % agarose in 25 mL anode buffer 
Anode buffer SDS running buffer (1x) 
Bromophenol blue (1%) 50 mM Tris, 1 % bromophenol blue 
Cathode buffer SDS running buffer (2x) 
DIGE stop solution 10 mM lysine 
Labeling buffer 7 M urea, 2 M thiourea, 2 % CHAPS, 30 mM 
Tris-Base 
Rehydration buffer 7 M urea, 2 M thiourea, 2 % CHAPS, 50 μl 
bromophenol blue 1 % 
Rehydration solution 500 µL rehydration buffer + 10 µl IPG-Puffer pH 
7-11 + 12.5 µl DeStreak 
SDS equilibration buffer 50 mM Tris-HCl pH 8,8, 30 % glycerol (99 %), 
6 M urea, 0,002 % bromophenol blue, 2 % SDS 
SDS running buffer (10x) 250 mM Tris, 1,92 M glycine, 1 % SDS 
  
5.1.3.3 Immunoblotting analysis 
NativePAGE™ Running Buffer 
(1x) 
50 mM BisTris, 50 mM Tricine pH 6.8 
Coomassie Brilliant Blue 0.165 g Coomassie G-250, 85 mL methanol, 
5.8 mL phosphoric acid, 42.5 g ammonium 
sulfate, filled up to 250 mL with deionized water 
Dark blue cathode buffer 10 mL NativePAGE™ Running Buffer (20x), 
10 mL NativePAGE™ Cathode Additive, filled 
up to 180 mL with deionized water 
Digitonin solution  20 % digitonin in deionized water 
Light blue cathode buffer 10 mL NativePAGE™ Running Buffer (20x), 
1 mL NativePAGE™ Cathode Additive, filled up 
to 189 mL with deionized water 
TBS-T 10 mM Tris-HCl, pH 7.4; 150 mM NaCl; 0.02% 
Tween 20 
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5.1.3.4 SERVA Purple protein stain 
Solution 1 850 mL deionized water, 10 g citric acid, 
150 mL ethanol 
Solution 2 1 L deionized water, 6.2 g boric acid, 3.85 g 
NaOH; pH > 9.4 
Solution 3 850 mL deionized water, 150 mL ethanol 
5.1.3.5 LC-MS/MS for metabolic analysis 
Solvent A 0.1 % acetic acid and 0.025 % HFBA in water 
Solvent B 
 
0.1 % acetic acid, 0.025 % HFBA, in acetonitrile 
5.1.3.6 High-resolution respirometry 
Mitochondria respiration medium 
(MiR05) 
0.5 M EGTA, 3mM MgCl2
.6H20, 60 mM 
potassium lactobionate, 20 mM taurine, 10 mM 
KH2PO4, 20 mM HEPES, 110 mM sucrose, 1 
g/L BSA, pH 7.1 
5.1.3.7 LC-MS/MS for proteomic analysis 
Solvent A 0.1% formic acid in water 
Solvent B 0.1% formic acid in acetonitrile 
 
5.1.4 Antibodies 
Primary antibody Supplier Dilution 
Custom-made Anti-EHHADH 
rabbit polyclonal IgG 
Epitope: 
EPSDYLRRLVAQGSPPLK 
Davids Biotechnologie GmbH, 
Regensburg, Germany 
1 : 1,000           
1 : 1,250 
Anti-HADHB 
Santa Cruz Biotechnolgy, 
Heidelberg, Germany 
1 : 200 
Anti-HADHA 
Santa Cruz Biotechnolgy, 
Heidelberg, Germany 
1 : 1,000   
Anti-EHHADH antibody 
(ab93172) 
Abcam pIc, Cambridge, United 
Kingdom 
1 : 160 
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Secondary antibody Supplier Dilution Modification 
Alexa Fluor
®
 488 goat anti-
rabbit 
Invitrogen, Karlsruhe, 
Germany 
1 : 400 
Alexa Fluoro
®
 
488 
ECL Rabbit IgG, HRP-linked 
whole antibody from donkey 
GE Healthcare Europe 
GmbH, Munich, Germany 
1 : 4,500 
HRP 
conjugated 
ECL Mouse IgG, HRP-linked 
whole antibody from sheep 
GE Healthcare Europe 
GmbH, Munich, Germany 
1 : 4,500 
HRP 
conjugated 
Bovine anti-goat IgG-HRP 
conjugated 
Santa Cruz Biotechnolgy, 
Heidelberg, Germany 
1 : 2,500 
HRP 
conjugated 
 
5.1.5 Kits, turnkey solution, marker 
10 % DDM solution Invitrogen GmbH, Darmstadt, Germany 
Amersham ECL Plus ™ Western 
Blotting Detection Reagents 
GE Healthcare Europe GmbH, Munich, Germany 
Amersham ECL Plus™ Western 
Blotting Detection Reagents 
GE Healthcare Europe GmbH, Munich, Germany 
ATP Colorimetric/Fluorometric 
Assay Kit  
BioVision Inc., Milpitas, CA, USA 
Casy
®
ton electrolyte Roche Diagnostics Deutschland GmbH, Mannheim, 
Germany 
DeStreak GE Healthcare Europe GmbH, Freiburg, Germany 
Fetal Bovine Serum Gold GE Healthcare Europe GmbH, Freiburg, Germany 
Fluorescence mounting medium Dako Deutschland GmbH, Hamburg, Germany 
FluoroProfile Kit Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
HOE33342 (Stockkonz.: 5x10-4 M); 
Dilution 1 : 400 
Invitrogen, Karlsruhe, Germany 
Hygromycine B solution Merck KGaA, Darmstadt, Germany 
IPG-Buffer pH 7-11 GE Healthcare Europe GmbH, Munich, Germany 
L-glutamine PAN Biotech GmbH, Aidenbach, Germany 
MassChrom
®
 internal standard 
labeled amino acids and 
acylcarnitines 
Chromsystems Instruments & Chemicals GmbH, 
Gräfelfing, Germany 
MEM alpha medium GE Healthcare Europe GmbH, Freiburg, Germany 
MitoTracker
®
 Orange Invitrogen, Eugene, Oregon USA 
NativePAGE™ Cathode Additive 
(20x) 
Invitrogen GmbH, Darmstadt, Germany 
NativePAGE™ Running Buffer (20x) Invitrogen GmbH, Darmstadt, Germany 
NativePAGE™ sample buffer Invitrogen GmbH, Darmstadt, Germany 
NuPAGE
®
 Antioxidant Invitrogen GmbH, Darmstadt, Germany 
NuPAGE
®
 LDS sample buffer (4x) Invitrogen GmbH, Darmstadt, Germany 
NuPAGE
®
 MOPS SDS Running 
Buffer (20x) 
Invitrogen, Karlsruhe, Germany 
NuPAGE
®
 Transfer Buffer (20x) Invitrogen, Karlsruhe, Germany 
PBS buffer Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Penicillin/streptomycin PAN Biotech GmbH, Aidenbach, Germany 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
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Pierce
®
 Protein A/G Magnetic 
IP/Co-IP Kit 
Thermo Fisher Scientific, Bonn, Germany 
Ponceau staining ready-to-use 
solution 
Carl Roth GmbH + Co KG, Karlsruhe, Germany 
Proteinase Inhibitor Cocktail Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
Refraction-2D Labeling kit NH DyeAGNOSTICS GmbH, Halle, Germany 
RotiBlock
®
 Carl Roth GmbH + Co KG, Karlsruhe, Germany 
RPMI 1640 without L-glutamine PAN Biotech GmbH, Aidenbach, Germany 
RPMI 1640 without L-glutamine and 
glucose 
PAN Biotech GmbH, Aidenbach, Germany 
SERVA Purple protein stain SERVA Electrophoresis GmbH, Heidelberg, Germany 
Tetracycline solution Bioline GmbH, Luckenwalde, Germany 
Trypsin  Promega GmbH, Mannheim, Germany 
Trypsin-EDTA PAN Biotech GmbH, Aidenbach, Germany 
 
5.1.6 Consumable Material 
1.5-mL and 2-mL Eppendorf 
microcentrifuge tube 
VWR International GmbH, Darmstadt, 
Germany 
10-kDa spin column Pall GmbH, Dreieich, Germany 
15 mL and 50 mL Röhrchen Greiner Bio-One GmbH, Frickenhausen, 
Germany 
96-well microplate  Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Axxygen
®
 Microcentrifuge Tube 
0.7 mL 
Fisher Scientific GmbH, Schwerte, Germany 
CASY
®
 cups Roche Diagnostics Deutschland GmbH, 
Mannheim, Germany 
Cell culture flask Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Cell scraper Techno Plastic Products AG, Trasadingen, 
Switzerland 
Cover glasses, 24 mm diameter VWR International GmbH, Darmstadt, 
Germany 
Immobiline™ DryStrip pH GE Healthcare Europe, München, Germany 
Myco Trace PAA Laboratories, Cölbe, Deutschland 
NativePAGE™ 3-12% Bis-Tris gel Invitrogen GmbH, Darmstadt, Germany 
NativePAGE™ 4-16% Bis Tris gels Invitrogen GmbH, Darmstadt, Germany 
NuPAGE
®
 Novex
®
 12% Bis Tris 2D 
well gel 
Invitrogen GmbH, Darmstadt, Germany 
NuPAGE
®
 Novex
®
 4-12% Bis-Tris 
protein gel 
Invitrogen GmbH, Darmstadt, Germany 
ProteoGel™ IPG Strip, 7 cm, pH 8-
11 linear 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
PVDF membrane Immobilon P Merck Millipore GmbH, Schwalbach, Germany 
Sample cups GE Healthcare Europe, München, Germany 
Sterile syringe filter 0.45 µm and 
0.2 µm 
VWR International GmbH, Darmstadt, 
Germany 
Whatman
®
 Paper Biometra, Göttingen, Germany 
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LC columns 
SLB-IL59 column (30 m x 0.25 mm inner diameter, 
0.2 µm film thickness) 
Supelco, Belafonte, PA, 
USA 
Acclaim PepMap column (75 µm I.D. x 25 cm, 
3 µm, C18) 
 Dionex, Idstein, Germany 
Atlantis T3 (3 µm, 2.1 mm i.d. x 150 mm) reversed 
phase column 
Waters, Eschborn, 
Germany 
Acclaim PepMap Precolumn (100 µm I.D. x 2 cm, 
5 µm, C18) 
 Dionex, Idstein, Germany 
 
5.1.7 Chemicals 
1,4-dithio-D-threitol (DTT) Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Acetic acid, LC-MS grade Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Acetonitrile, LC-MS grade Fisher Scientific GmbH, Schwerte, 
Germany 
Acetyl coenzyme A lithium salt Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Acrylamide 4K-Lösung 37.5:1 (30%)  AppliChem, Darmstadt, Germany 
Adenosine 5 diphosphate 
monopotassium salt dihydrate from 
bacterial source 
Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Agarose, low-melting Bio-Rad Laboratories GmbH, Munich, 
Germany 
Ammonium persulfate Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
Ammoniumsulfate Merck KGaA, Darmstadt, Germany 
Antimycin A from Streptomyces sp. Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Boric acid SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Bovine serum albumin  Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Bovine serum albumin, fatty acid free GE Healthcare Europe GmbH, Freiburg, 
Germany 
Bromophenol blue GE Healthcare Europe GmbH, Freiburg, 
Germany 
CaCl2 Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Caproic acid Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
CHAPS AppliChem, Darmstadt, Germany 
Citric acid SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Coomassie Brilliant Blue G-250 Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
51 
 
Cytochrome C from Horse Heart   Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Digitonin Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
DTNB  Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
EDTA, Disodium salt Dihydrat  Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
EGTA  Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Ethanol p.a. J.T. Baker, Deventer, Netherlands 
FCCP Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Formic acid p.a. Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Glucose Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
Glycerol AppliChem, Darmstadt, Germany 
Glycine Merck KGaA, Darmstadt, Germany 
HEPES  Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
HFBA  Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Iodoacetamide Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
K2HPO4 Merck KGaA, Darmstadt, Germany 
KH2PO4 Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
L-ascorbic acid Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
L-carnitine Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
L-lysine Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Malic acid Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Methanol VWR International GmbH, Darmstadt, 
Germany 
MgCl2*6H20 Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
MOPS AppliChem, Darmstadt, Germany 
NaCl Merck KGaA, Darmstadt, Germany 
NaOH  Merck KGaA, Darmstadt, Germany 
NaOH pellets SERVA Electrophoresis GmbH, 
Heidelberg, Germany 
Oligomycin Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Oxaloacetic acid Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Palmitic acid Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
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Palmitoylcarnitine Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Palmitoyl-CoA Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Paraformaldehyde Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Ortho-phosphoric acid Merck KGaA, Darmstadt, Germany 
Potassium lactobionate Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Rotenone Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
SDS Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
Skimmed milk powder Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
Sodium pyruvate Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Succinic acid Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Sucrose Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Taurine Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
TEMED GE Healthcare Europe GmbH, Freiburg, 
Germany 
TMPD Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Tris USB Corporation, Cleveland, OH USA 
Tris-HCl  Carl Roth GmbH + Co KG, Karlsruhe, 
Germany 
Trition X-100 Sigma-Aldrich Chemie GmbH, Munich, 
Germany 
Tween 20 Merck KGaA, Darmstadt, Germany 
Urea GE Healthcare Europe GmbH, Freiburg, 
Germany 
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5.1.8 Devices 
4000 Qtrap
®
 LC/MS/MS System AB SCIEX GmbH, Framingham, 
MA, USA 
Agilent 1200 SL HPLC system Böblingen, Germany 
Agilent model 6890 GC with a Mass Selective 
Detector (MSD) model 5975 Inert XL 
Agilent, Palo Alto, CA, USA 
Amersham Biosciences Ultrospec 3100 pro GE Healthcare Europe GmbH, 
Munich, Germany 
Autoklav Systec VX-55 Systec, Wettenberg, Germany 
Bandelin Sonorex Ultraschallbad Schalltec, Mörfelden-Walldorf, 
Germany 
Bio-Rad VersaDoc Imaging System 4000 MP Bio-Rad Laboratories GmbH, 
Munich,Germany 
CASY
®
 TT Cell Counter + Analyzer Schärfe System GmbH, Reutlingen, 
Germany 
Concentrator 5301 Eppendorf, Hamburg, Germany 
ECL Semi-Dry Tranfer Unit TE 77 GE Healthcare Europe GmbH, 
Munich, Germany 
Ettan™ IPGphor™ 3 IEF System GE Healthcare Europe, München, 
Germany 
Fluorostar Optima microplate reader BMG Labtech GmbH, Ortenberg, 
Germany 
Heraeus
®
 HERAcell 240 CO2 Inkubator Thermo Fisher Scientific, 
Langenseldbold, Germany 
Heraeus
®
 HERAsafe HSP12 Thermo Fisher Scientific, 
Langenseldbold, Germany 
Heraeus
®
 Multifuge3S-R Thermo Fisher Scientific, 
Langenseldbold, Germany 
Micromax RF Microcentrifuge Thermo Fisher Scientific, 
Langenseldbold, Germany 
Oroboros-2k Oxygraph OROBOROS Instruments, 
Innsbruck, Austria 
pH meter Lab 850 SI Analytics, Mainz, Germany 
Purelab plus USF Deutschland, Ransbach-
Baumbach, germany 
Qstar XL MS/MS System AB SCIEX Germany GmbH, 
Darmstadt, Germany 
Shaker Rotamax 120 Heidolph, Schwabach, Germany 
Shaker with tumbling motion 3012 Gesellschaft für Labortechnik, 
Burgwedel, Germany 
TripleTOF
®
 5600+ System AB SCIEX Germany GmbH, 
Darmstadt, Germany 
Ultimate3000 nano-RP-HPLC-system  Dionex, Idstein, Germany 
vacuum evaporator CombiDancer, Hettich AG, Bäch, 
Switzerland 
Wilovert S inverse microscope with phase contrast Helmut Hund, Wetzlar, Germany 
XCell II™ Blot Module CE Mark  Invitrogen, Karlsruhe, Germany 
XCell SureLock™ Mini-Cell Invitrogen, Karlsruhe, Germany 
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5.1.9 Software 
Analyst version 1.5 AB SCIEX Germany GmbH, Darmstadt, 
Germany 
Analyst version 1.6TF AB SCIEX Germany GmbH, Darmstadt, 
Germany 
DatLab software version 
4.3.4.70 
OROBOROS Instruments, Innsbruck, 
Austria 
MarkerView™ version 1.2.1 ABSciex, Darmstadt, Germany 
Mascot 2.3 Search Algorithm Matrix Science Inc, Boston, MA, USA 
PeakView™ 2.1 ABSciex, Darmstadt, Germany 
Progenesis SameSpots 4.1 Nonlinear Dynamics Limited, Newcastle 
upon Tyne, United Kingdom 
Quantity One Bio-Rad Laboratories GmbH, Munich, 
Germany 
Protein Pilot 4.5 ABSciex, Darmstadt, Germany 
 
5.2 Methods 
5.2.1 Cell culture work 
5.2.1.1 Cell culture conditions 
The LLC-PK1 cell line was cultivated in the respective media at 37 °C, 5% CO2, in a 
saturated humid air incubator. All cell culture work was carried out under sterile 
conditions in a biological safety cabinet. The cell culture was tested regularly for 
mycoplasma infection using the PCR-based Myco Trace kit.  
5.2.1.2 Thawing and cultivation of the cell line 
The cell line was stored in liquid nitrogen in a mixture consisting of 90% heat-
inactivated FCS and 10% DMSO. Following removal from liquid nitrogen, the cells 
were transported on ice. The cell line was rapidly thawed, transferred into a 75-cm2 
cell culture flask with prewarmed routine cell culture medium, and placed in the 
incubator. The next day, the medium was exchanged for fresh medium and the cells 
were incubated at 37 °C for another day.  
Cell culture medium was exchanged every other day. At a confluence of 80 – 90%, 
cells were split for further subcultivation. For subcultivation, the confluent cells were 
washed twice with prewarmed PBS and trypsinized for 8 min at 37 °C by adding 3 
mL Trypsin-EDTA. The reaction was stopped by the addition of 8 mL medium, before 
transfer of the cells into a sterile 15-mL Falcon tube. The tube was centrifuged at 
125 x g, 5 min, 8 °C. The cells were resuspended in prewarmed fresh medium and 
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seeded in a 75-cm2 flask at a subcultivation ratio of 1:3 to 1:8, as required for further 
stimulation or cultivation. 
5.2.1.3 Cell count measurement 
For cell counting, the CASY® cell counter + analyzer was used. The cells were 
passaged, resuspended in fresh medium, and diluted 1:200 in Casy®ton electrolyte. 
Care was taken to prevent the formation of cell aggregates, as cells have to pass 
individually through the capillary for accurate counting. The CASY® cell counter + 
analyzer makes use of the resistance measurement principle.  
5.2.1.4 Stimulation of LLC-PK1 cells 
The LLC-PK1 cell line had been stably transfected with either EHHADHWT or 
EHHADHMUT cDNA using the inducible Tet-on gene expression system. For 
stimulation, the cells were seeded in either stimulation medium 1 or 2 at a density of 
0.25 x 106 cells / mL and grown for seven days. Tetracycline was added at a final 
concentration of 1 µg / mL with every changing of the medium. During the 7-day 
stimulation period, cells were allowed to grow to confluency.  
Stimulation medium 1 was employed for Western blot analysis of EHHADH on a 2D-
gel and co-immunoprecipitation experiments. For all other experiments, stimulation 
medium 2 was used. 
5.2.1.5 Selection of transfected cell line 
The cells were regularly controlled for mistargeting of EHHADHMUT into mitochondria 
and overexpression of both EHHADHWT and EHHADHMUT by means of 
immunofluorescence staining.  
For selection, if necessary, cells were grown for 3-4 weeks in routine cell growth 
medium containing 200 µg / mL hygromycin B and checked for successful selection 
by means of immunofluorescence staining. 
 
5.2.2 Immunofluorescence staining 
For immunofluorescence staining, cells were stimulated for seven days on sterile 
cover glasses with a diameter of 24 mm. Cells were then incubated for 4 additional 
hours in stimulation medium supplemented with tetracycline and 1:50,000 diluted 
MitoTracker® Orange, which stains selectively mitochondria in living cells. Afterwards, 
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the cells were washed for 5 min with Ringer solution. For fixation of the cells, the 
cover glass with the adherent cells was incubated in 3 % PFA in PBS buffer for 30 
min and then washed three times 5 min each with Ringer solution. For the 
subsequent antibody incubation, cells were permeabilized for 5 min in PBS/0.1 % 
SDS and washed three times, 5 min each, with PBS. For incubation with primary 
antibody, anti-EHHADH was used at a dilution of 1:1,000 in PBS/0.04 % Triton X-100 
and incubated for 90 min at room temperature. The cells were washed between the 
primary and secondary antibody three times for 5 min each with PBS. The secondary 
antibody incubation (Alexa 488 goat anti-rabbit at a 1:400 dilution in PBS/0.04 % 
Trition X-100) was done for 1 hour at room temperature. Simultaneously, the cell-
permeant nuclear counterstain Hoechst 33342 was added at a 1:400 dilution. 
Hoechst 33342 shows blue fluorescence when bound to double-strand DNA. Finally, 
cells were washed for 5 min with PBS, before the cover glasses were mounted with 
aqueous mounting medium and stored at 4 °C in the dark until inverse fluorescence 
microscopy. 
While I carried out the immunfluorescence staining myself, the mounting of the cover 
glasses and the detection of the stain by microscopy were performed at the Institute 
of Medial Cell Biology by Carsten Broecker (PhD student). 
The excitation and emission wavelengths used are shown in Table 3. 
 
Table 3: Filter used for immunoflurescence staining. 
  Excitation wavelength 
Emission 
wavelength 
MitoTracker
®
 Orange 530 – 555 nm 575 – 630 nm 
Hoe333422 365 nm 420 – 470 nm 
Anti-EHHADH with secondary 
antibody Alexa Fluor
®
 488 goat 
anti-rabbit 
 
465 – 495 nm 515 – 555 nm 
 
5.2.3 Isolation of mitochondria  
For isolation of mitochondria, a subcellular fractionation was performed. To that end, 
cells were washed three times with ice cold PBS and centrifuged at 500 x g and 4 °C 
for 5 min. The pellet was resuspended in 3 mL of mitochondria isolation buffer 
containing 1 % phosphatase and 0.1 % proteinase inhibitor cocktail, respectively. 
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Cells were disrupted by sonification (2x20 seconds / 20 % pulsation) and centrifuged 
at 1,500 x g and 4 °C for 5 min to pellet nuclei and intact cells. In the following, a 
centrifugation step with the supernatant at 12,000 x g, 15 min, 4 °C was conducted to 
obtain the cytoplasmic fraction in the supernatant and the mitochondria in the pellet. 
The mitochondria fraction was resuspended in 500 μL of isolation buffer and spun at 
12,000 x g for 15 min. The resulting mitochondria containing pellet was resuspended 
in 300 μL of isolation buffer. Isolated mitochondria and an aliquot of whole-cell-lysate 
were stored at -80 °C until further analysis. A scheme of the differential centrifugation 
is shown in Figure 10. Protein amount was quantified using the FluoroProfile® kit 
according to the manufacturer´s protocol.  
 
 
Figure 10: Scheme of the differential centrifugation procedure used. 
 
5.2.4 BSA-fatty acid complex 
Palmitic acid presents the bulk of the dietary fatty acids and is β-oxidized within the 
mitochondria. As palmitic acid is water insoluble, it is bound to bovine serum albumin 
as a carrier for cellular experiments. For the preparation of the BSA-fatty acid 
complex, 40 μL of 1 M NaOH were added to 2 mL stock solution of 0.125 M palmitic 
acid in 100% ethanol. The solution was dried for 30 min in a vacuum concentrator. 
The residuum was dissolved in 500 μL of hot (60 – 70 °C) water and slowly added to 
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glucose-free RPMI 1640 containing 0.2% fatty acid free BSA under continuous 
stirring at 37 °C. Thereafter, the medium was sterile filtered through a filter with a 
pore size of 0.2 μm, The absolute concentration of palmitic acid in the medium was 
determined by GC-MS and adjusted to 0.3 ± 0.02 mM. 
 
5.2.5 SDS-PAGE with subsequent immunoblot analysis 
5.2.5.1 Time series for EHHADH overexpression 
A stimulation time series over six days was performed with the LLC-PK1 cell line to 
investigate the time-dependent expression of EHHADH within six days of stimulation. 
For immunoblot analysis, 20 μg of total protein were separated on a 4-12% Bis-Tris 
gel run for 20 min and 60 min each at 50 V and 200 V, respectively. Afterwards, the 
gel was blotted for one hour at 25 V on a PVDF membrane (0.45 μm). Transfer 
efficiency was monitored by Ponceau staining. The blot was blocked first overnight at 
4 °C in TBS-T + 5% milk powder, and then incubated for an additional hour at room 
temperature, before it was washed in TBS-T once for 15 min and then two times for 
5 min. Subsequently, the blot was incubated with a 1:1,250 dilution of anti-EHHADH-
antibody for 90 min at room temperature followed by three washing steps with TBS-T 
(once 15 min and twice 5 min). For binding of the secondary antibody (ECL Rabbit 
IgG, HRP-linked whole antibody from donkey) a 1:4,500 dilution and an incubation 
period of one hour at room temperature were used. After further washing steps, the 
blot was developed using Amersham ECL Plus™ Western Blotting Detection 
Reagents, and after 5 min the chemiluminescence signal was detected by means of 
a Bio-Rad VersaDoc 4000 MP imaging system. 
 
5.2.5.2 Analysis of mistargeting of EHHADH by immunoblotting 
Immunoblot analyses of whole cell lysate and purified mitochondria of EHHADHWT 
and EHHADHMUT were performed. On a NuPAGE
® Novex 4-12% Bis Tris gel, 3 μg of 
whole cell lysate and 3 μg of purified mitochondria were loaded and run at 50 V for 
20 min and at 200 V for 60 min. After the run, proteins were blotted from the gel with 
the XCell II™ Blot Module CE Mark onto a 0.45 μm PVDF membrane for 1 hour at 25 
V. Further analysis was carried out as described above. 
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5.2.6 Two-dimensional differential in-gel electrophoresis 
A 2D-DIGE approach was used to determine EHHADH on a 2D gel. To that end, 
25 μg of whole cell lysate in labelling buffer from either EHHADHWT or EHHADHMUT 
cells were labeled with cyanine dyes (Cy3 and Cy5) before the analysis, according to 
manufacturer´s protocol. In this analysis, EHHADHWT and EHHADHMUT were labeled 
with Cy3 and Cy5, respectively. The IPG strip was rehydrated in rehydration solution 
overnight. For the first dimension, a 7-cm IPG-strip with a pH range from pH 8 to 11 
was used. Isoelectric focussing was performed using the Ettan IPGphor 3 for a total 
of 28.5 kVhrs, with cup loading on the acidic end of the IPG strip, using the gradient 
shown in Table 4. After isoelectric focusing, the IPG strips were equilibrated first in 
SDS equilibration buffer containing 130 mM DTT for 20 min to reduce disulfide bonds 
followed by incubation in SDS equilibration buffer containing 280 mM iodoacetamide 
for 20 min to alkylate the thiol groups. The equilibrated IPG strips were laid on a 10% 
acrylamide gel and the second dimension was run for 20 min at 50 V and then for 
100 min at 120 V in a XCell SureLock® Mini-Cell Electrophoresis System. After the 
run, images were taken by the Bio-Rad VersaDoc 4000 MP imaging system. 
 
Table 4: Program for isoelectric focussing on the Ettan IPGphor 3. 
Voltage (V) time (h) 
Step and voltage 
methode 
40 2 Step´n´Hold 
100 1 Step´n´Hold 
500 4 Gradient 
1000 3 Gradient 
1000 2 Step´n´Hold 
4000 12 Step´n´Hold 
 
In addition, an immunoblot analysis of the same gel was performed to localize 
EHHADH on the 2D-gel. To that end, proteins were blotted after imaging from the gel 
for one hour at 25 V onto a PVDF membrane (0.45 μm) by means of the XCell II™ 
Blot Module CE Mark. Protein transfer was monitored by Ponceau staining and the 
blot was blocked overnight at 4 °C using Rotiblock®. The blot was incubated for an 
additional hour at room temperature in TBS-T + 5% milk powder and washed in TBS-
T for 15 min and two times for 5 min. For the anti-EHHADH-antibody, a dilution of 
1:1,250 and an incubation time of 90 min at room temperature were used, followed 
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by three washing steps with TBS-T (once for 15 min and twice for 5 min each). For 
binding of the secondary antibody (ECL Rabbit IgG, HRP-linked whole antibody from 
donkey), a dilution of 1:4,500 and an incubation time of one hour at room 
temperature were used. After further washing steps, the blot was developed using 
Amersham ECL Plus™ Western Blotting Detection Reagents, and after 5 min the 
chemiluminescence signal was detected using a Bio-Rad VersaDoc 4000 MP 
imaging system. Using the Quantity One software an overlay picture was generated 
(Figure 2B). 
 
5.2.7 Co-Immunoprecipitation 
5.2.7.1 Co-immunoprecipitaton of EHHADH 
To find possible mitochondrial interaction partners of EHHADHMUT, a co-
immunoprecipitation with a commercial EHHADH antibody and the Pierce® Protein 
A/G Magnetic IP/Co-IP Kit was performed. First, an immune complex was formed by 
adding 10 μg of EHHADH antibody to 360 μg of isolated mitochondria from either 
EHHADHWT or EHHADHMUT cells and overnight incubation at 4 °C. Next, 25 μg of 
Pierce Protein A/G Magnetic beads were transferred to a 1.5-mL microcentrifuge 
tube and washed by adding 175 μL of IP Lysis/Wash Buffer and gentle mixing. The 
tube was placed in a magnetic stand to collect the magnetic beads against one side 
of the tube and the supernatant was discarded. Two further washing steps were 
performed by adding each time 1 mL of IP Lysis/Wash Buffer and repeated inversion 
of the tube for 1 min, before the magnetic beads were collected and the supernatant 
was discarded. Subsequently, the antigen sample/antibody mixture was added to the 
prewashed magnetic beads and incubated at room temperature for 3 h under 
continuous mixing. After the incubation, the beads were collected with a magnetic 
stand. The unbound proteins were removed and the magnetic beads were washed 
three times. In the last washing step, 500 μL of ultrapure water was added to the 
magnetic beads, which were then collected by a magnetic stand. For the elution step, 
100 μL of 2x LDS sample buffer was added to the magnetic beads and incubated for 
10 min under continuous mixing. The resulting supernatant, including the protein-
protein complex of interest, was saved for further analysis. A scheme of the working 
procedure is shown in Figure 11. 
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Afterwards, a diagonal two-dimensional SDS-PAGE was performed with the co-
immunoprecipitated samples. Briefly, 20 μL of sample was loaded on a NuPAGE® 
Novex 4-12% Bis Tris gel and run under non-reducing conditions at 50 V for 20 min 
and at 200 V for 60 min. After the first gel run, the lanes for EHHADHWT and 
EHHADHMUT were cut out, equilibrated for 15 min in NuPAGE
® LDS sample buffer 
with 0.05 M DTT, and placed on top of a NuPAGE® Novex 12% Bis Tris gel. The 
second gel runs were performed under reducing conditions with the addition of 
NuPAGE® Antioxidant to the cathode buffer chamber. The gels were run as 
described above and stained with Coomassie Brilliant Blue over night before they 
were placed in deionized water for destaining. Images of the gels were acquired 
using the Bio-Rad VersaDoc 4000 MP imaging system. Every visible spot was 
excised, washed, digested with trypsin and extracted with 5% formic acid before 
analysis by nano-HPLC-QTOF-MS/MS. Proteins were identified using the Mascot 
Distiller software. 
Analyses were accomplished by means of a QStar XL MS/MS system (AB Sciex, 
Darmstadt, Germany) coupled to an Ultimate 3000 nano-HPLC-system with 
precolumn concentration (100 µm I.D., 2 cm length, 5 µm Acclaim PepMap, flow-rate 
5 µL/min). The samples were separated on a 25 cm-column (75 µm I.D., 3 µm 
Acclaim PepMap) at a flow-rate of 300 µL/min using a 212-min gradient from 4-40% 
B. The QStar XL mass spectrometer was operated in IDA-mode acquiring first a 
TOF-scan from 350-1250 Da for 1 s, followed by product ion scans for 2.5 s for the 
two most intense ions. MS/MS spectra were searched against the NCBInr database 
(August 2013) using the ProteinPilot software (version 4.5) applying a 1% FDR.  
 
5.2.7.2 Co-immunoprecipitation of HADHB 
Co-immunoprecipitation against HADHB was performed, as both subunits, HADHA 
and HADHB, are possible interaction partners of mislocalized EHHADH. The Pierce  
Protein A/G Magnetic IP/Co-IP Kit was used in this experiment. For the formation of 
the immune complex 500 μg of isolated mitochondria from either EHHADHWT or 
EHHADHMUT cells were incubated with 10 μg HADHB antibody over night at 4 °C. 
Further steps of co-immunoprecipitation were performed as described above. 
Afterwards, immunoblot analyses against HADHA, HADHB and EHHADH were 
performed. Briefly, 15 μL of co-immunoprecipitation sample of either EHHADHWT or 
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EHHADHMUT was separated on a 4-12% Bis-Tris gel for every antibody used for the 
immunoblot analysis. Afterwards, the gel was blotted for one hour at 25 V on a PVDF 
membrane (0.45 μm Immobilon P). Transfer efficiency was monitored by Ponceau 
staining, and the blot was blocked over night at 4 °C in TBS-T + 5% skimmed milk 
powder. After incubation for an additional hour at room temperature, the  membrane 
was washed three times in TBS-T, once for 15 min and twice for 5 min each, and 
incubated with anti-EHHADH antibody (1:1,250), anti-HADHB antibody (1:200), and 
for the anti-HADHA antibody (1:1,000), respectively, for 90 min at room temperature. 
The membrane was washed again trice with TBS-T and incubated with an 
appropriate HRP-linked secondary antibody to anti-EHHADH and anti-HADHA (ECL 
Rabbit IgG, whole antibody from donkey, 1:4,500 dilution) and anti-HADHB (Bovine 
anti-goat IgG-HRP, 1:2,500 dilution) for one hour at room temperature. After further 
washing steps, the blot was developed using Amersham ECL Plus™ Western 
Blotting Detection Reagents, and after a 5-min incubation the chemiluminescence 
signal was detected using the Bio-Rad VersaDoc 4000 MP imaging system. 
 
 
Figure 11: Working procedure for co-immunoprecipitation with the Pierce® Protein A/G 
Magnetic IP/Co-IP Kit 
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5.2.8 Blue native PAGE analysis 
5.2.8.1 Incorporation of EHHADHMUT into MTP 
For blue native PAGE, 125 μg of isolated mitochondria from either mutated or wild-
type transfected LLC-PK1 were centrifuged at 12,000 x g and 4 °C for 15 min to 
pelletize intact mitochondria. The organelle proteins were solubilized in cold 
NativePAGE™ sample buffer containing 0.5% DDM by pipetting up and down and 
repeated inversion. After incubation on ice for 15 min, samples were centrifuged at 
20,000 x g and 4 °C for 30 min to pelletize the non-solubilised organelle proteins. The 
supernatant was transferred to an Eppendorf tube and stored at -80 °C until further 
use. Before loading of the samples, the wells of the NativePAGE™ 4-16% Bis-Tris 
gels were filled with dark blue native cathode buffer for better visualization of sample 
wells. Samples were first run at 150 V for 20 min, then the dark blue cathode buffer 
was replaced with light blue cathode buffer, before the gel was run at 50 V and 250 
V, respectively, for 1 hr each. The gel was then electroblotted to a PVDF membrane 
(0.45 μm) at 25 V for one hour using the XCell II™ Blot Module CE. Subsequently, 
the membrane was incubated in 20 mL of 8% acetic acid for 15 min rinsed with 
deionized water and, finally, air-dried. Prior to immunoblot analysis, the membrane 
was rewetted in 100% methanol, rinsed with deionized water, and incubated 
overnight in TBS-T + 5% skimmed milk powder. After incubation for an additional one 
hour at room temperature, the membrane was washed in TBS-T once for 15 min and 
two times for 5 min each, and then incubated with anti-EHHADH-antibody (1:1,250) 
and anti-HADHB-antibody (1:200), respectively, for 90 min at room temperature, 
followed by repeated washing with TBS-T (once for 15 min and twice 5 min each). 
The membrane was then incubated with the appropriate secondary antibody to anti-
EHHADH (ECL Rabbit IgG, HRP-linked whole antibody from donkey) and anti-
HADHB (bovine anti-goat IgG-HRP conjugated) at dilutions of 1:4,500 and 1:2,500, 
respectively, for one hour at room temperature. After further washing steps the blot 
was developed using Amersham ECL Plus™ Western Blotting Detection Reagents. 
After 5 min of incubation the chemiluminescence signal was detected using a Bio-
Rad VersaDoc 4000 MP imaging system. 
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5.2.8.2 2D blue native / SDS-PAGE analysis 
For 2D blue native / SDS-PAGE with subsequent immunoblot analysis, 75 µg of 
isolated mitochondria form either EHHADHWT or EHHADHMUT LLC-PK1 cells were 
prepared as outlined above using a digitonin concentration of 4 g / g protein. 
Mitochondrial proteins were separated on a NativePAGE™ 3-12% Bis-Tris gel for 
30 min at 150 V with dark blue cathode buffer and, subsequently, 2 h 50 min, at 
250 V, with light blue cathode buffer. Lanes were cut out of the blue native gel, 
equilibrated first for 15 min in SDS equilibration buffer with 54 mM DTT, followed by 
15-min equilibration in SDS equilibration buffer supplemented with 0.1 M IAA. Lanes 
were then rotated by 90° and laid onto a 12% Bis Tris 2D well gel. The gels were run 
in the second dimension for 40 min at 50 V and for 2 hours at 200 V. Subsequently, 
the separated proteins were transferred by semi-dry electroblotting to a PVDF 
membrane (0.45 µm) for two hours at 45 mA and blocked overnight with RotiBlock®. 
For subsequent immunoblot analysis, blots were washed once in TBS-T for 15 min 
and two times for 5 min each. Blots were then incubated with anti-EHHADH-antibody 
(1:1,250) for 90 min at room temperature followed by washing with TBS-T (once for 
15 min and twice for 5 min each). For binding of the secondary antibody to anti-
EHHADH a dilution of 1:4,500 was used (ECL Rabbit IgG, HRP-linked whole 
antibody from donkey) and incubated for one hour at room temperature. After further 
washing steps, the blot was developed using Amersham ECL Plus™ Western 
Blotting Detection Reagents, and after 5 minutes incubation the chemiluminescence 
signal was detected using a Bio-Rad VersaDoc 4000 MP imaging system. 
 
5.2.9 Metabolic analysis 
5.2.9.1 ATP measurement 
Measurement of ATP content was achieved using the ATP Colorimetric/Fluorometric 
Assay Kit from BioVision Inc. according to the manufacturer’s instructions. Briefly, 
stimulated cells were lysed with ATP Assay Buffer and deproteinized using a 10-kDa 
spin column. Fifthy µL of either EHHADHWT or EHHADHMUT cell lysate were added to 
a 96-well plate. For every sample of EHHADHWT or EHHADHMUT an ATP 
measurement and a background measurement were carried out. A standard curve 
was prepared ranging from 0.025 to 1.0 nmol ATP / well, with six calibrations points, 
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and water as control. To each sample and standard, 50 µL of reaction mixture were 
added, containing 45.8 µL ATP Assay Buffer, 0.2 µL ATP Probe, 2.0 µL ATP 
Converter and 2.0 µL Developer. For the background, 50 µL of reaction mixture was 
added, containing 47.8 µL ATP Assay Buffer, 0.2 µL ATP Probe and 2.0 µL 
Developer. 
Protected from light, the reactions were incubated for 30 min at room temperature. 
Fluorescence was measured using the Fluorostar Optima plate reader, with an 
excitation wavelength of 535 nm and an emission wavelength of 587 nm. The 
measurements were replicated four times each for the EHHADHWT or EHHADHMUT 
LLC-PK1 cells.  
 
5.2.9.2 Acylcarnitine measurement 
For acylcarnitine analysis, an aliquot of 1 mL of cell culture stimulation medium with 
palmitic acid was centrifuged at 1,500 x g, 4 °C for 5 min to pelletize the cells. The 
supernatant was then transferred to a new Eppendorf tube. Acylcarnitines were 
extracted by adding 300 µL of 80% aqueous methanol and 100 µL of MassChrom® 
internal standard labeled amino acids and acylcarnitines to 100 µL of cell culture 
supernatant, followed by centrifugation at 10,000 x g, 8 °C, for 5 min. The 
supernatant was dried for 75 min in a vacuum evaporator, reconstituted in 100 µL of 
50 % aqueous methanol, and analyzed by LC-ESI-MS/MS. The experiment was 
replicated four times.  
5.2.9.3 Acetyl-CoA measurement 
For acetyl-CoA analysis, the cell culture medium was replaced by ice cold PBS and 
washed three times, before 2 mL cold 80% aqueous methanol was added and the 
cells were detached using a cell scraper as described previously 68. For experiments 
with unlabeled palmitic acid, a 5 µM internal standard of acetyl-1,2-13C2-CoA was 
added, for experiments with 13C-labeled palmitic acid no internal standard was 
added. Extracts were evaporated and reconstituted in 70 µL of ultrapure water 
immediately prior to LC-ESI-MS/MS analysis. 
5.2.9.4 Palmitic acid uptake 
For determination of the fatty acid uptake rates of EHHADHMUT and EHHADHWT, the 
uptake of palmitic acid from cell culture medium was measured. The cells were 
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incubated with stimulation medium 2 for 48 hrs. Subsequently, culture supernatants 
obtained from EHHADHMUT and EHHADHWT cells, respectively, were centrifuged at 
1,500 x g, 4 °C, for 5 min to pelletize the cells and the supernatants were transferred 
to new tubes. The palmitic acid content of the supernatants and a medium control 
incubated for 48 hrs was measured by GC-MS after transesterification of palmitic 
acid with methanol to its corresponding methyl ester according to Masood et al. 69. 
The working group of Katja Dettmer-Wilde at the Institute of Functional Genomics 
performed the GC-MS analysis on an Agilent model 6890 GC that was equipped with 
a Mass Selective Detector (MSD) model 5975 Inert XL. GC was performed using an 
SLB-IL59 column (30 m x 0.25 mm inner diameter, 0.2 µm film thickness). Samples 
were injected in splittless modet at 280 °C, with an injection volume of 1 µL. The 
gradient for the GC separation was ramped at 5 °C/min from an initial oven 
temperature of 50 °C to 290 °C and held for 5 min. As carrier gas, helium was used 
at a constant flow rate of 0.7 mL/min. The mass spectrometer was operated in full 
scan mode from 50-550 m/z. Quantification was performed using a calibration curve 
for palmitic acid methyl ester with [U-13C]palmitic acid methyl ester serving as an 
internal standard. 
 
5.2.9.5 LC-ESI MS/MS analysis 
LC-ESI-MS/MS was carried out on an Agilent 1200 SL HPLC system using an 
Atlantis T3 (3 µm, 2.1 mm i.d. x 150 mm) reversed phase column (Waters, Eschborn, 
Germany). The flow-rate was 350 and 400 µL*min-1 for the acylcarnitine and acetyl-
CoA analysis, respectively. The gradient for the former was 0-8 min 0% B, 8-11 min 
100% B, 11-11.1 min from 100% to 0% B, and 0% B for 8.9 min. The gradient for the 
acetyl-CoA measurement was as follows: 0-5 min 5 % B, 5-17 min linear increase 
from 5 to 30% B, 17-19 min hold 30% B, 19-20 min linear increase from 30 to 90% B, 
20-21 min increase from 90 to 95% B, 21-24 min hold 95 % B, 24-25 min decrease 
from 95 to 5% B, 25-30 min hold 5% B. The injection volume was 10 µL for both 
methods. The HPLC system was directly coupled to an AB-Sciex 4000 QTrap® mass 
spectrometer. Acylcarnitines and acetyl-CoA were quantified by multiple reaction 
monitoring (MRM) in positive ionization mode with a dwell time of 300 ms, using the 
parameters listed in Supplemental Table 1. Data analysis was performed by Analyst 
version 1.5 (AB-Sciex). 
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5.2.10 High resolution respirometry 
5.2.10.1 Substrate-uncoupler-inhibitor titration protocol 
High-resolution respirometry was performed at the Chair of Medical Cell Biology to 
check whether the transfected EHHADHMUT cell line showed a phenotype in 
respiration comparable to that of the wild-type transfected cell line. For high-
resolution respirometry, cells were harvested as described under the cell culture work 
section and resuspended in MiR05. Cell density was measured by means of a Casy® 
Cell Counter + Analyser System. Respiration per cell was measured with an 
Oroboros-2k oxygraph, which features two chambers, for the parallel measuring of 
two samples. Prior to use, both chambers of the oxygraph were filled with 2.1 mL of 
MiR05 medium each, equilibrated with oxygen at 37 °C, and calibrated for oxygen 
saturation. Next, the media were replaced with 2.8 mL cell suspension in MiR05 at 
37 °C, of which 700 µL were removed and directly frozen in liquid nitrogen for citrate 
synthase activity measurements. The chambers were closed with stoppers and the 
respiration rates were measured. The cell suspensions were continuously stirred at 
750 rpm. The measurements were corrected for instrumental background, which had 
been determined in a separate experiment, and the data were recorded and 
analyzed using the DatLab software (version 4.3.4.70). For high-resolution 
respirometry, the substrate-uncoupler-inhibitor titration protocol shown in Table 5 was 
used. The experiments with the EHHADHWT and EHHADHMUT cell lines were 
repeated a minimum of n = 10. Oxygen flux was normalized to citrate synthase 
activity. 
 
Table 5: Substrate-uncoupler-inhibitor titration protocol for high-resolution respirometry 
measurements. 
Substrate/Uncoupler/Inhibitor Volume (µL) Final concentration 
Malate 5 2 mM 
Digitonin 3 12.2 µM 
Palmitoylcarnitine 2 1 µM 
Adenosine diphosphate (ADP) 20 5 mM 
Glutamate / Pyruvate 10 / 5 10 mM / 5 mM 
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Table 5 (continued) 
Substrate/Uncoupler/Inhibitor Volume (µL) Final concentration 
Cytochrome C 5 10 µM 
Succinate 20 10 mM 
Oligomycin 2 4 µg/ml 
FCCP 1 / 1 / 1 0.5 µM / 1 µM / 1.5 µM 
Rotenone 2 0.1 µM 
Antimycin A 1 2.5 µM 
Ascorbate / Tetramethyl-p-
phenylenediamine (TMPD) 
20 / 5 8 mM / 0.5 mM 
 
5.2.10.2 Inhibition of palmitoyl-CoA on respiration 
In a second experiment, high-resolution respirometry was employed to measure the 
inhibition of respiration by long-chain acyl-CoAs. The cells were stimulated by the 
substrate-uncoupler-inhibition titration protocol shown in Table 5, except for the 
addition of palmitoylcarnitine. After the induction of maximal phosphorylation capacity 
by the addition of succinate, palmitoyl-CoA was added at a final concentration range 
of 10 – 60 µM to the oxygraph chamber, and the decrease in respiration was 
measured. In addition, controls were included, but measured in the absence of 
palmitoyl-CoA. The inhibition experiments with the EHHADHWT and EHHADHMUT cell 
lines were repeated a minimum of n = 4. 
5.2.11 Citrate synthase activity measurement 
The activity of citrate synthase was measured spectrophotometrically by means of an 
Amersham Biosciences Ultrospec 3100 pro. Seven hundred µL of cell suspension 
were prewarmed for 10 min at 37 °C. One hundred µL of cell suspension were added 
to 900 µL of prewarmed (37 °C) incubation medium containing 700 µL ultrapure 
water, 100 µL 0.1 mM DTNB in 1 M Tris-HCl buffer, pH 8.1, 25 µL 10 % Trition X-
100, 50 µL 10 mM oxaloacetate in 0.1 mM triethanolamine-HCl-buffer, pH 8.0, 25 µL 
acetyl-CoA, mixed carefully and the linear increase in absorbance was measured 
every 20 s at 412 nm over 200 s 70. The device automatically calculated the slope of 
the enzyme kinetics. Citrate synthase activity was then used for normalization of 
oxygen flux. 
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5.2.12 Respiratory chain supercomplex assembly 
For the quantification of supercomplex formation, a blue native PAGE of isolated 
EHHADHWT or EHHADHMUT mitochondria was performed. For blue native PAGE, 
200 µg of sample were prepared as stated above, with a digitionin concentration of 
4 g / g protein. The samples were separated on a NativePAGE™ 3-12% Bis-Tris gel 
according to the manufacturer´s protocol and, subsequently, stained with the SERVA 
Purple protein stain. For staining of the 1D gel, the gels were fixed for 1 h at room 
temperature in Solution 1. The gels were then stained for 1.5 h in Solution 2, to which 
the SERVA Purple concentrate had been added at a 1:250 dilution immediatedly 
prior to staining. The gels were washed by gentle rocking in Solution 3 for 30 min 
prior to acidification of the gels in Solution 1 for 30 min. The stain was visualized 
using the VersaDoc 4000 MP imaging system and quantified by the Bio-Rad software 
Image Lab. The analysis was repeated seven times and values normalized to 
complex V.  
 
5.2.13 SWATH™ analysis 
One hundred µg of total cell lysate were used for filter-aided sample preparation 
using 30 kDa centrifugal filter units as described by Wisniewski et al. 71. Ten µL of 
total cell lysate of either EHHADHWT or EHHADHMUT cells were used for nano-LC-
MS/MS-analysis. Analyses were accomplished by means of a TripleTOF 5600+ 
QTOF mass spectrometer (AB Sciex, Darmstadt, Germany) coupled to an Ultimate 
3000 nano-HPLC-system with precolumn concentration (100 µm I.D., 2 cm length, 5 
µm Acclaim PepMap, flow rate 5 µL/min). The samples were separated on a 25 cm-
column (75 µm I.D., 3 µm Acclaim PepMap) at a flow rate of 300 µL/min using a 212-
min gradient from 4-40% B. For generation of the peptide library, the mass 
spectrometer was operated in independent data acquisition (IDA) mode, acquiring 
first a TOF-scan from 350-1250 Da for 250 ms, followed by product ion scans of the 
25 most intensive signals for 100 ms each (m/z-range 230-1500 Da). MS/MS spectra 
were searched against the NCBInr database (August 2013) using the ProteinPilot 
software (version 4.5) applying a 1% FDR. For SWATH™-analyses the same HPLC-
conditions were applied, but the mass spectrometer conducted a 50 ms TOF-scan 
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followed by 37 SWATH-windows (100 ms each; m/z-range 230-1500 Da) spanning a 
precursor-m/z-range of 350-1250 Da. SWATH™-data was processed using the 
PeakView™- and MarkerView™-software. Up to six unique, unmodified peptides per 
protein with six transitions per peptide were used for quantification, data was 
normalized to total intensity, and pairwise t-tests were conducted. Analyses were 
carried out in triplicate. 
 
5.2.14 Statistical analysis 
A one-way ANOVA test was used for comparison between more than two groups. 
Statistical analysis between two groups were made using the paired Student´s t-test. 
A p-value ≤ 0.05 was considered to be statistically significant. For multiple testing, the 
method of Benjamin and Hochberg 72 was used to adjust the p-value by controlling 
the false discovery rate (FDR).  
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6 Results 
6.1 Stable overexpression and localization of EHHADH 
6.1.1 Time series for EHHADH overexpression 
A stable overexpression of EHHADHWT and EHHADHMUT is a requirement for all 
following analyses. Therefore, over the first six days of stimulation, every day whole 
cell lysate was taken and separated on a 4-12% Bis Tris gel, followed by immunoblot 
analysis using a custom-made anti-EHHADH. As shown in Figure 12, after 48 hours 
of stimulation, EHHADH was detected by immunoblot analysis. At day 4, EHHADH 
overexpression reached a plateau-phase that persisted thru day 6. 
 
 
 
Figure 12: Immunoblot analysis of stable overexpression of EHHADH during the first six days 
of stimulation. 
 
6.1.2 Analysis of mistargeting of EHHADH by immunoblotting 
The mistargeting of EHHADHMUT into mitochondria was confirmed by immunoblot 
analysis. The whole cell lysate of EHHADHMUT cells yielded a well resolved double 
band (Figure 13A), while the mitochondrial fraction of EHHADHwt cells did not yield 
any band. Only the lower band is obtained in isolated mitochondria of the 
EHHADHMUT cell line (Figure 13B). 
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Figure 13: Immunoblot analysis of total cell lysate and purified mitochondria of EHHADHWT and 
EHHADHMUT cells. Analyses of total cell lysates by immunoblotting showed a single band for 
EHHADHWT cells and a well-resolved double band for EHHADHMUT cells. In a purified mitochondrial 
protein extract of EHHADHWT cells, no EHHADH could be detected, whereas the extract of 
EHHADHMUT cells showed the lower molecular weight band of EHHADH. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein, Cell Rep., in 
revision) 
 
6.1.3  Control of mistargeting of EHHADHMUT by immunofluorescence 
staining 
The mistargeting of EHHADHMUT was verified regularly by immunofluorescence 
staining. An exemplary immunofluroescence staining is shown in Figure 14. For the 
EHHADHWT cell line, immunohistochemical staining against EHHADH showed a clear 
peroxisomal localization, as seen by the dotted pattern in green (Figure 14A). In 
Figure 14B the mitochondrial staining with MitoTracker® Orange of EHHADHWT cell 
line is shown. In the respective overlay of the peroxisomal protein EHHADH and 
MitoTracker® Orange (Figure 14C) it is obvious that no localization of EHHADHWT 
into mitochondria has occurred. In the EHHADHMUT cell line, the staining against 
EHHADH showed a more widespread localization (Figure 14D) compared to the 
EHHADHWT cell line. Figure 14E showed the mitochondrial staining of EHHADHMUT 
cell line. The overlay (Figure 14F) of EHHADHMUT cells showed, that EHHADHMUT 
was mistargeted to the mitochondria in addition to the expected peroxisomal 
localization, as shown by the yellow areas in the overlay.  
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Figure 14: Immunfluorescence staining of EHHADHWT cells shown in A-C and EHHADHMUT cells 
in D-F. A and D: Staining of EHHADH with a custom-made anti-EHHADH antibody; B and E: Staining 
of mitochondria with MitoTracker® Orange; C and F: Staining of nuclei with DAPI and overlay of 
staining for EHHADH and MitoTracker® Orange for the respective cell line; Scale bars are 10 µm. 
 
6.1.4  Two-dimensional differential in-gel electrophoresis 
In two-dimensional differential in-gel electrophoresis (2D-DIGE), up to three samples 
are labeled with fluorescence dyes (Cy2, Cy3 and Cy5). The labeled samples are 
mixed prior to classical 2D gel electrophoresis. 2D-DIGE overcomes some limitations 
of traditional 2D gel electrophoresis, like gel-to-gel variation, which facilitates the 
direct comparison of different specimens. In addition, small differences between wild 
type and mutated proteins, like a shift in pI between EHHADHWT and EHHADHMUT, 
can be distinguished. 
Therefore, 2D DIGE analysis of whole cell lysate of EHHADHWT cell line and 
EHHADHMUT cell line was performed. Figure 15A shows an overlay of the Cy3 and 
Cy5 images of the 2D DIGE gel, revealing a shift in pI between EHHADHWT and 
EHHADHMUT, with the latter being more basic. For the determination of the 
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localization of EHHADH in the 2D gel, an immunoblot analysis was carried out. 
Figure 15B shows the position of EHHADH on the 2D gel, which tallies with the 
protein spots for EHHADHWT and EHHADHMUT in Figures 15A.  
 
 
Figure 15: Two-dimensional differential in-gel electrophoresis of whole cell lysates of 
EHHADHWT and EHHADHMUT cell lines, respectively. A: Overlay image of 2D-DIGE gel of Cy3-
labeled EHHADHWT cell line (green) and Cy5-labled EHHADHMUT cell line (red). The overlay reveals a 
shift in pI between EHHADHWT cell line and EHHADHMUT cell line, where the latter shifts slightly to a 
basic pI. B: Immunoblot with custom-made anti-EHHADH antidody for detection of EHHADH in the 2D-
gel. 
 
6.2 Incorporation of mutated EHHADH into the mitochondrial 
trifunctional protein 
6.2.1 Co-immunoprecipitation of EHHADH and HADHB 
To find possible mitochondrial interaction partners of EHHADHMUT, co-
immunoprecipitation experiments with a commercial EHHADH-antibody were 
performed on mitochondrial protein extracts of EHHADHWT and EHHADHMUT cells, 
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respectively. The co-immunoprecipitates were subsequently used for diagonal two-
dimensional SDS-PAGE (non-reducing / reducing). The gel was stained with 
coomassie dye and every visible spot was cut out and prepared for nano-HPLC-
QTOF-MS/MS analysis.  
The subunits of the heterooctameric mitochondrial trifuctional protein (MTP), HADHA 
and HADHB, were identified as potential mitochondrial interaction partners of 
EHHADHMUT. Next, a co-immunoprecipitation of HADHB was conducted, followed by 
immunoblot analysis with anti-EHHADH, anti-HADHA, and anti-HADHB, respectively 
(Figure 16). Immunoblot analysis of mitochondria purified from EHHADHWT and 
EHHADHMUT cells, respectively, revealed HADHA to co-immunoprecipitate with 
HADHB. In addition, EHHADHMUT co-immunoprecipitated with HADHB, whereas no 
band was visible in mitochondria purified from EHHADHWT cells.  
 
 
Figure 16: Co-immunoprecipitation of HADHB from purified mitochondria of EHHADHWT and 
EHHADHMUT cells, respectively, with subsequent immunoblot analysis using anti-EHHADH, 
anti-HADHA, and anti-HADHB antibodies. The immunoblot analysis shows a band for EHHADH in 
the EHHADHMUT cell line, whereas no band is visible for the EHHADHWT cell line. For HADHA and 
HADHB, similar levels are found in both the EHHADHWT and the EHHADHMUT cell line.  
(Source: Klootwijk ED, Reichold M, Helip-Wooley A, et al. Mistargeting of peroxisomal EHHADH and 
inherited renal Fanconi's syndrome. N Engl J Med 2014;370:129-38.) 
 
6.2.2 Blue native PAGE analysis 
Blue native PAGE enables the separation of native protein complexes according to 
their mass. Purified mitochondria from EHHADHWT and EHHADHMUT cells were 
76 
 
analysed by blue native page followed by immunoblot analysis against HADHB and 
EHHADH (Figure17). The immunoblot against HADHB showed a band at about 
500 kDa for both the EHHADHWT and the EHHADHMUT cells in concordance with the 
expected molecular weight of native MTP complex (Figure 17A). In contrast, only the 
EHHADHMUT cell line yielded positive immunostaning against EHHADH at about 500 
kDa, whereas the EHHADHWT cell line lacked such signal (Figure 17B). 
 
 
Figure 17: Immunoblot analysis of mitochondria purified from EHHADHWT and EHHADHMUT 
cells. A: Immunoblot analysis of blue native PAGE against HADHB. B: Immunoblot analysis of blue 
native PAGE against EHHADH. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
6.3 Respiratory chain analysis 
6.3.1 High-resolution respirometry 
High-resolution respirometry is a method to analyse mitochondrial respiration in intact 
cells, permeabilized cells or isolated mitochondria. By means of substrate-uncoupler-
77 
 
inhibitor titration, it is possible to measure the function of individual complexes of the 
respiratory chain, or a combination of two or more complexes to exactly specify the 
site of disturbance in the respiratory chain. Results of high-resolution respirometry 
are shown in Figure 18. Endogeneous respiration of EHHADHWT and EHHADHMUT 
cell lines did not show a significant difference. Next, malate was added to stabilize 
the cells for subsequent permeabilization by the mild detergent digitonin. Following 
digitionin addition, the respiration was slightly decreased due to the absence of 
oxygen consuming side reactions that are not related to mitochondrial respiration. As 
substrate for β-oxidation, palmitoylcarnitine is added and the oxidative 
phosphorylation capacity via the electron transfer flavoprotein (ETF) is measured 
after the addition of ADP. The EHHADHMUT cell line showed a lower oxidative 
phosphorylation capacity than the EHHADHWT cell line. The addition of glutamate 
and pyruvate stimulates both complex I and ETF, so that one can determine their 
combined oxidative phosphorylation capacity. The oxygen consumption after the 
addition of glutamate and pyruvate did not increase further. EHHADHMUT cells still 
showed significantly decreased (p = 0.003) oxygen consumption compared to the 
EHHADHWT cell line. Cytochrome c is added to the chamber as a control for the 
integrity of the OMM. Damage done to the OMM during permeabilization causes 
leakage of cytochrome c into the buffer, with respiration becoming rate limiting as a 
consequence. A strong increase in respiration after the addition of exogeneous 
cytochrome c would therefore hint at damage of the OMM. Here, oxygen 
consumption after the addition of exogenous cytochrome c was hardly altered, thus 
confirming integrity of the OMM. Succinate is added as a substrate for complex II to 
reveal the maximum oxidative phosphorylation capacity in the coupled state. As 
before, the EHHADHMUT cell line showed a significant reduction (p = 0.001) in 
oxidative phosphorylation capacity compared to the EHHADHWT cell line. After the 
addition of succinate the difference in oxidative phosphorylation capacity between 
EHHADHWT and EHHADHMUT cell line was reduced to only 19 %, pointing towards a 
slight compensation in respiration differences, as the difference after the addition of 
palmitoylcarntine and pyruvate and glutamate (complex I) was 30 % and 33 %, 
respectively. ATP synthase is inhibited by the addition of oligomycin and the oxygen 
consumption which contributes to the LEAK respiration, is measured. The 
EHHADHMUT cell line showed a significantly decreased (p = 0.005) LEAK respiration 
compared to the EHHADHWT cell line. The addition of FCCP (Carbonyl cyanide p-
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trifluoro-methoxyphenyl hydrazine) uncouples the electron transport of the respiratory 
chain from oxidative phosphorylation system. The mitochondrial respiration is 
typically limited by the oxidative phosphorylation system and, thus, after uncoupling 
the maximum respiration possible is measured. As the oxygen consumption of 
EHHADHMUT cell line is still significantly decreased even after uncoupling, this 
displays that the defect in respiration is located in the oxidative phosphorylation 
machinery as well as in the electron transport system. After the rotenone-induced 
inhibition of complex I, the respiration of complex II in the uncoupled state was also 
reduced in the EHHADHMUT cell line. The oxygen consumption linked to ATP 
production was calculated for the substrates pyruvate/glutamate and 
palmitoylcarnitine for complex I and ETF, respectively. For both substrates, oxygen 
consumption was reduced by 22 % and 35 % in EHHADHMUT cells, respectively.  
 
 
Figure 18: High-resolution respirometry analysis of the EHHADHWT and EHHADHMUT cell lines. 
Endo: enodgeneous respiration; Palm: palmitoylcarnitine; Glut/Pyr: glutamate and pyruvate; Cyt C: 
cytochrome c; Succ: succinate; Oligo: oligomycin; O2-ATP: calculated oxygen consumption linked to 
ATP production for the substrates glutamate and pyruvate; O2-ATP Palm: calculated oxygen 
consumption linked to ATP production for the substrate palmitoylcarnitine; values are means ± SEM; 
* FDR adjusted p-value ≤ 0.05. 
 
The addition of palmitoyl-coenzyme A as an inhibitor of mitochondrial respiration is 
shown in Figure 19. Palmitoyl-CoA was exogeneously added to the chamber and led 
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to a significant, dose-dependent decrease in respiration at a concentration as low as 
20 µM.  
 
 
 
Figure 19: Inhibition of respiration by palmitoyl-CoA. The addition of palmitoyl-CoA to actively 
respiring permeabilized cells shows at a concentraton of 20 µM palmitoyl-CoA and higher a significant, 
dose-dependent decrease in respiration; shown are the means ± SEM of four independent 
measurements each; * ANOVA with pairwise t-test and FDR adjusted p ≤ 0.05 (in relation to control).  
 
An artificial inhibition, by palmitoyl-CoA, to the same level as EHHADHMUT cell line, 
was also accomplished. Thereby the impact of palmitoyl-CoA on mitochondrial 
respiration was investigated. Both cell lines showed the same percentage of inhibition 
of respiration for complex I and II in both the coupled and the uncoupled state.  
 
6.3.2 Interaction analysis of EHHADH with the respiratory chain by 2D-
blue native/ SDS-PAGE with subsequent immunoblot analysis 
For the analysis of the interaction of EHHADH with the respiratory chain complexes 
and supercomplexes, 2D blue-native / SDS-PAGE was carried out. Isolated 
mitochondria from both the EHHADHWT and the EHHADHMUT cell line were separated 
according to their mass in their native state in the first dimension. In the second 
dimension, the respiratory chain complexes and supercomplexes were resolved into 
their individual subunits. The incorporation of EHHADTMUT within the respiratory 
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chain supercomplexes and the interaction of EHHADHMUT with complex I are shown 
by means of immunoblot analysis against EHHADH, whereas no band is visible for 
EHHADH in the EHHADHWT cell line (Figure 20). In addition, a band was visible at 
~ 500 kDa, the molecular mass of MTP, supporting once again the incorporation of 
EHHADHMUT into the MTP.  
 
 
Figure 20: 2D blue native / SDS-PAGE analysis of isolated mitochondria from EHHADHWT and 
EHHADHMUT cell line with subsequent immunoblot analysis against EHHADH. In EHHADHMUT 
cells a band for EHHADH is visible within the individual subunits of respiratory chain complex I and 
supercomplexes, indicating the interaction of EHHADHMUT with complexe I and respiratory chain 
supercomplexes. Also a band at ~ 500 kDa, the molecular mass of MTP, is visible in EHHADHMUT 
cells. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
6.3.3 Quantification of supercomplex assembly 
An exemplary 1D blue native PAGE, which was stained with SERVA Purple protein 
stain for quantification of supercomplex assembly, is shown in Figure 21A. 
Densitometric analysis (Figure 21B) with the Image Lab software showed a 44% 
decrease in supercomplex formation in the EHHADHMUT cell line, from a 
supercomplex / complex V ratio of 0.7 ± 0.09 to 0.39 ± 0.05.  
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Figure 21: Quantification of supercomplex formation in mitochondria isolated from the 
EHHADHWT and EHHADHMUT cell line, respectively. A: Exemplary 1D blue native PAGE stained 
with SERVA Purple protein stain. B: Densitometric analysis of supercomplex formation with the Image 
Lab software. Values represent means ± SEM; * p ≤ 0.05. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
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6.4 Metabolic analysis 
6.4.1 Palmitic acid uptake 
To calculate uptake rates of palmitic acid in EHHADHMUT and EHHADHWT cells, 
changes in palmitic acid levels in cell culture media over 48 hours were measured by 
means of GC-MS. The EHHADHMUT cell line took up significantly less (p = 0.016) 
palmitic acid (Fig 22). 
 
   
Figure 22: Analysis of palmitic acid uptake by EHHADHWT and EHHADHMUT cells. The 
EHHADHMUT cell line takes up significantly less palmitic acid. Values are means ± SEM; * p ≤ 0.05. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
6.4.2 Metabolic analysis of acetyl-CoA 
LC-MS/MS analysis of unlabeled, intracellular levels of acetyl-CoA did not show a 
significant difference between the EHHADHWT and the EHHADHMUT cell line. 
However, the analysis of 13C-labelled acetyl-CoA in cells grown on 13C-labelled 
palmitic acid, showed a significantly reduced level (p < 0.04) of 13C-labelled acetyl-
CoA in the EHHADHMUT cell line upon normalization to total acetyl-CoA (Fig 23). 
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Figure 23: LC-MS/MS analysis of 
13
C-labelled acetyl-CoA in the EHHADHWT and EHHADHMUT cell 
lines. EHHADHMUT cell line showed a decreased level of 
13
C-labelled acetyl-CoA, when grown on 
13
C-
labelled palmitic acid, compared to EHHADHWT cell line. Values are means ± SEM; * p-value ≤ 0.05.  
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
6.4.3 Acylcarnitne analysis 
Acylcarnitine analysis is an essential tool for screening of fatty acid β-oxidation 
defects. The analysis of long-chain acylcarnitines in cell culture supernatant (Figure 
24) showed a significant increase in long-chain acylcarnitines as well as long-chain 
ketoacyl- and hydroxyacylcarntines in EHHADHMUT cells compared to EHHADHWT 
cells. The extracellular concentration of 3-hydroxyhexadecanoylcarnitine ((4S)-4-[(3-
hydroxyhexadecanoyl)oxy]-4-(trimethylazaniumyl)butanoate) was even below the 
detection limit of the method in the EHHADHWT cell line.  
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Figure 24: Analysis of long-chain acylcarnitines in cell culture supernatants. Compared to 
EHHADHWT cells, levels of long-chain acylcarnitines as well as ketoacyl- and hydroxyacyl carnitines 
were significantly elevated in EHHADHMUT cells. In EHHADHWT cells, 3-hydroxyhexadecanoylcarntine 
could not be quantified. Values are means ± SEM; * FDR adjusted p-value ≤ 0.05. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
6.4.4 Measurement of ATP content 
The EHHADHMUT cell line showed a significantly decreased (p < 0.012) content of 
ATP (1.74 ± 0.26 nmolATP / mg protein) compared to the EHHADHWT cell line (3.15 
± 0.14 nmol ATP / mg protein). 
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Figure 25: Measurment of ATP content in the EHHADHWT and EHHADHMUT cell lines. Values are 
means ± SEM; * p ≤ 0.05. As glycerol phosphate generates background in this assay, for every 
measured sample a background measurement was carried out from the same sample. Afterwards, the 
value of the background was substracted from the value of the sample prior to further calculations. 
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
6.5 Proteomic analysis 
The SWATH-MS™ analysis revealed a significant regulation of proteins involved in 
the respiratory chain, fatty acid β-oxidation and the tricarboxylic acid cycle (Table 6). 
Seven out of ten identified subunits of complex I were significantly downregulated in 
the EHHADHMUT cell line. For complex III, no clear trend in regulation was obvious: 
one of the two out of five subunits identified was significantly downregulated, while 
the other one was markedly up-regulated in the EHHADHMUT cell line. For complex 
IV, two out of six identified subunits were significantly down-regulated in the 
EHHADHMUT cell line. Only four out of fourteen complex V subunits were significantly 
regulated, but they did not show the same trend of regulation, as two subunits each 
were either significantly down- or upregulated. In addition, several constituents of 
fatty acid β-oxidation were significantly regulated. The peroxisomal multifunctional 
protein type 2 was significantly downregulated in the EHHADHMUT cell line, whereas 
peroxisomal bifunctional isoform 1 and acyl-CoA binding protein were significantly 
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upregulated. In addition, the ADP/ATP translocase 2 and mitochondrial dicarboxylate 
carrier isoform 2 were significantly downregulated in EHHADHMUT cell line. 
 
Table 6: Results of Swath™ analysis. The table lists the respective NCBI accession numbers, the 
functional class membership of a protein, the fold-change observed in the EHHADHMUT cell line, and 
the calculated p-values. Negative fold-changes mean a down-regulation and positive fold-changes an 
up-regulation in the EHHADHMUT cell line. 
NCBInr 
Accession 
Protein Functional Class 
Fold-
change 
p-value 
Respiratory Chain 
gi|311276243 
PREDICTED: NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 11, 
mitochondrial-like isoform 2 [Sus scrofa] 
-3,7 5,3844E-06 
gi|511887496 
PREDICTED: NADH dehydrogenase 
[ubiquinone] 1 subunit C2 [Mustela putorius 
furo] 
-8,0 8,6342E-05 
gi|432102533 
NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 10 [Myotis davidii] 
-8,2 0,00087 
gi|516267059 
NADH dehydrogenase subunit I 
[Blastomonas sp. AAP53] 
-5,4 0,01125 
gi|311272935 
PREDICTED: NADH-ubiquinone 
oxidoreductase 75 kDa subunit, mitochondrial 
isoform 1 [Sus scrofa] 
-2,1 0,01273 
gi|83286812 
NADH-ubiquinone oxidoreductase complex 
[Bos taurus] 
-2,2 0,01676 
gi|335310208 
PREDICTED: NADH dehydrogenase 
[ubiquinone] 1 beta subcomplex subunit 4-
like [Sus scrofa] 
-2,5 0,03047 
gi|73994981 
PREDICTED: cytochrome b-c1 complex 
subunit 9 isoform 2 [Canis lupus familiaris] 
-4,1 0,00029 
gi|350581652 
PREDICTED: cytochrome b-c1 complex 
subunit 2, mitochondrial-like [Sus scrofa] 
7,6 0,02365 
gi|350584800 
PREDICTED: cytochrome c oxidase subunit 
4 isoform 1, mitochondrial-like [Sus scrofa] 
-3,3 0,00017 
gi|471368705 
PREDICTED: cytochrome c oxidase subunit 
5A, mitochondrial-like [Trichechus manatus 
latirostris] 
-5,6 0,02243 
gi|529007286 
PREDICTED: ATP synthase subunit f, 
mitochondrial isoform X2 [Bos taurus] 
-12,8 0,00106 
gi|113205874 
ATP synthase subunit O, mitochondrial 
precursor [Sus scrofa] 
-12,6 4,3098E-07 
gi|350580769 
PREDICTED: ATP synthase subunit delta, 
mitochondrial-like [Sus scrofa] 
2,2 0,00214 
gi|465982382 
PREDICTED: ATP synthase subunit e, 
mitochondrial [Orcinus orca] 
2,4 0,01472 
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Table 6 (continued) 
NCBInr 
Accession 
Protein Functional Class 
Fold-
change 
p-value 
Fatty acid β-oxidation 
gi|47523670 
peroxisomal multifunctional enzyme type 2 
[Sus scrofa] 
-2,4 0,01141 
gi|68989263 
peroxisomal bifunctional enzyme isoform 1 
[Homo sapiens] 
6,3 0,00032 
gi|47523046 acyl-CoA-binding protein [Sus scrofa] 3,0 0,01409 
Mitochondrial transporters 
gi|512904223 
PREDICTED: ADP/ATP translocase 2 
[Heterocephalus glaber] 
-20,6 0,00025 
gi|470595839 
PREDICTED: mitochondrial dicarboxylate 
carrier isoform 2 [Tursiops truncatus] 
-2,8 0,00254 
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7 Discussion 
7.1 Localization and mistargeting of EHHADHMUT 
Proteins containing a peroxisomal targeting sequence are imported into peroxisomes 
in their fully folded or oligomeric state 60, with further processing occurring only for a 
subset of proteins. In contrast, proteins featuring a mitochondrial targeting sequence 
are imported in their unfolded state and the N-terminal mitochondrial targeting 
sequence is cleaved after the import into the mitochondrial matrix, leading to a 
shortened mature protein 59.  
The peroxisomal protein EHHADH, which is involved in peroxisomal fatty acid 
oxidation, features the typical peroxisomal C-terminal targeting sequence SKL. The 
mutation p.E3K, which replaces a negatively charged glutamic acid residue with a 
positively charged lysine, generates a novel mitochondrial targeting sequence at the 
N-terminal end. Cleavage of this mitochondrial targeting sequence upon import is 
indicated by the well-resolved double band on gels of whole cell lysate, indicating a 
shift of ~ 2 kDa in size (Figure 13). Actually, EHHADHMUT is only partly mistargeted 
into mitochondria. Most is still targeted to peroxisomes, as shown by 
immunofluorescence staining (Figure 14F), where in addition to the mislocalized 
EHHADHMUT (yellow areas), EHHADHMUT was mainly localized to the peroxisomes. 
Furthermore, in immunoblot analysis of EHHADHMUT cells was shown that in addition 
to the mitochondrial localized EHHADHMUT, indicated by the band in the 
mitochondrial fraction of EHHADHMUT cells, we also saw a band for the peroxisomal 
localized EHHADHMUT, appearing at the same height as the wild type EHHADH. The 
erroneous localization of EHHADHMUT is not a specific phenomenon of the cell line 
LLC-PK1, as transfection of COS7 and HEK293 cells also showed mistargeting of 
EHHADHMUT 
67
.  
Mutation of EHHADH also causes changes in the proteins´ properties. The isoelectric 
point of a protein is defined at the pH, at which the protein carries no electric net 
charge. For EHHADHWT protein, the pI is 9.8 
64, and through the exchange of a 
negatively changed amino acid against a basic amino acid, the pI of the protein shifts 
to a slightly more basic value. However, taking into account the import of 
EHHADHMUT into mitochondria and the cleavage of the mitochondrial targeting 
sequence, the pI will become more acidic. In 2D-DIGE, a shift of EHHADHMUT to the 
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basic is seen. The major part of EHHADHMUT is still localized to the peroxisomes, 
thereby the exchange of an amino acid influencing the pI is apparent more than the 
cleavage of the mitochondrial targeting sequence. Thus, an overall shift of the pI of 
EHHADHMUT is seen more to the basic. 
 
 
7.2 Erroneous interaction of EHHADHMUT with the mitochondrial 
trifunctional protein 
Mistargeting of EHHADHMUT into mitochondria leads to the interaction of EHHADHMUT 
with the mitochondrial trifunctional protein (MTP) as shown by co-
immunoprecipitation. As part of the mitochondrial β-oxidation spiral of fatty acids, 
MTP catalyzes the last three steps of mitochondrial β-oxidation of long-chain fatty 
acids. The MTP consists of four alpha subunits, HADHA, bearing the enoyl-CoA 
hydratase and the L-3-hydroxyacyl-CoA dehydrogenase activity, and four beta 
subunits, HADHB, bearing the ketoacyl-CoA thiolase activity. Together, they build a 
heterooctamer, which is located in the IMM. Co-immunoprecipitation against 
EHHADH led to the identification of HADHA and HADHB as potential interaction 
partners of EHHADHMUT. For verification of this interaction, co-immunoprecipitation 
against HADHB was performed. The corresponding immunoblot yielded a band for 
EHHADHMUT cells, whereas no band was visible for EHHADHWT cells, indicating an 
interaction of EHHADHMUT with MTP.  
This interaction was investigated in more detail by means of blue native PAGE, which 
separates protein complexes according to their native state. Blue native PAGE of 
mitochondria purified from both EHHADHWT and EHHADHMUT cells with subsequent 
immunoblot analysis against EHHADH and HADHB was performed. The immunoblot 
analysis against EHHADH (Figure 17B) showed for EHHADHWT no band, whereas 
for EHHADHMUT a band was visible at ~ 500 kDa, corresponding to the expected 
molecular weight of intact MTP complex, thus confirming once more the interaction of 
EHHADHMUT with the native MTP complex. 
Interaction of EHHADHMUT with MTP may occur in two ways, either by the additional 
attachment of an EHHADHMUT subunit to the MTP complex, or via the replacement of 
an MTP subunit against an EHHADHMUT. An additional attachment of EHHADHMUT to 
the complex will enlarge the molecular mass of the complex by ~ 77 kDa. The fact, 
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that no such shift was observed in the immunoblot against HADHB (Figure 17A), 
points towards an exchange of EHHADHMUT for a subunit of the MTP, instead of an 
additional attachment of EHHADHMUT to the complex.  
The native EHHADH has a mass of 79 kDa, and EHHADHMUT after processing in the 
mitochondrial matrix has a mass of ~ 77 kDa. The masses of the alpha and beta 
subunits of MTP are 79 kDa and 47 kDa, respectively. While an exchange for a beta-
subunit will result in an increase of ~ 30 kDa, an exchange for an alpha-subunit will 
increase the mass of the MTP complex by only ~ 2 kDa. Therefore, the observed 
result points towards an exchange of EHHADHMUT for the alpha-subunit of the 
complex rather than an additional attachment of EHHADHMUT to the complex or the 
exchange of a beta-subunit.  
 
7.3 Effects of mistargeting of EHHADHMUT on mitochondrial fatty 
acid β-oxidation  
Incorporation of EHHADHMUT into the MTP leads to impairment of mitochondrial β-
oxidation of long-chain fatty acids. As a consequence, long-chain acylcarnitines 
accumulate in the cell culture supernatant (Figure 25). A well-known clinical 
parameter for fatty acid oxidation disorders is acylcarnitine profiling in neonates by 
tandem mass spectrometry (MS/MS) 73-78. As fatty acid oxidation disorders (FAOD) 
are an often fatal inherited group of metabolic disorders, it is important to diagnose 
these disorders pre-symptomatically by newborn screening, to reduce infant mortality 
rate and start early with an appropriate diet. The EHHADHMUT cell line showed 
increased amounts of tetradecanoylcarnitne and hexadecanoylcarnitine and their 
corresponding long-chain enoyl- and hydroxyacylcarnitines in the cell culture 
supernatant. This increase in long-chain acylcarnitines and their fatty oxidation 
intermediates are indicative for an impairment of mitochondrial β-oxidation in the 
EHHADHMUT cell line. Impaired mitochondrial β-oxidation leads to accumulation of 
imported long-chain acyl-CoAs and intermediates of mitochondrial β-oxidation. As 
these compounds are harmful to cellular functions, they are exported via the CPT II 
and CACT in the reverse direction out of the mitochondria into the cytosol and are 
excreted from the cell as their corresponding long-chain acylcarnitine, by a yet 
unknown mechanism 79. Ventura et al. 79 showed that CPT II accepts palmitoyl-CoA 
as well as its β-oxidation intermediates as substrates, which are transported by the 
91 
 
carnitine-acylcarnitine translocase into the cytosol and exported out of the cell. This 
reverse action of CPT II and CACT lowers the intramitochondrial amount of cytotoxic 
long-chain acyl-CoAs and recycles coenzyme A (CoA). Zierz et al. 80 also showed, 
that the forward reaction of total CPT was inhibited by 0.1 mM D,L-palmitoylcarnitine 
by 55 %. This inhibtion of the total CPT forward reaction was only present for L- and 
D,L-palmitoylcarntinine but not for D-palmitoylcarnitine, indicating that the effect was 
due to a substrate inhibition and not a detergent-like effect 80. In addition, they also 
stated that the CPT fraction, which showed the inhibition by palmitoylcarnitine, 
represented the CPT II activity 80. 
Further, both Zierz et. al. 80 and Ventura et. al. 79 showed, that the accumulation of 
long-chain acylcarnitines led to substrate inhibition of the forward reaction of CPT II 
and increased the reverse reaction of CPT II and CACT leading to the export of long-
chain acylcarnitines into the cytosol and out of the cell. The extracellular level of long-
chain acylcarnitines and their fatty acid oxidation intermediates resemble the situation 
in patients with MTP deficiency 81, although in a less severe form. This is not 
surprising, as in contrast to MTP deficiency not all MTP complexes are expected to 
contain EHHADHMUT. Consequently, mitochondrial β-oxidation is affected less than in 
classical cases of inherited MTP deficiency. 
 
7.4 Impact of impaired mitochondrial fatty acid β-oxidation on 
other cellular mechanisms 
The disturbance of mitochondrial fatty acid β-oxidation affects other pathways and 
molecular mechanisms up- and downstream of β-oxidation.  
7.4.1 Uptake of exogeneous long-chain fatty acids 
The uptake of palmitic acid over a period of 48 hours was reduced significantly in the 
EHHADHMUT cell line (Figure 22). Import of fatty acids (FA) across the cellular 
membrane is facilitated by two processes, diffusion and protein-mediated import by 
FATPs. Diffusion is one possible way to support metabolism, when FAs are present 
at high concentrations. However, under physiological conditions, diffusion is not 
sufficient to supply enough FA for energy generation, so that a protein-mediated 
mechanism is required to efficiently mediate transbilayer transport of FAs 82,83. 
Integral membrane-bound fatty acid transport proteins (FATPs) facilitate the transport 
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of FAs into the cell. To prevent the efflux of the FAs, they are activated by the action 
of acyl-CoA synthetases. This process is ATP dependent and, therefore, depletion of 
ATP may cause decreased uptake of FAs. The uptake of long-chain fatty acids via 
protein-mediated mechanisms are also regulated by downstream factors, like 
mitochondrial long-chain fatty acid uptake, re-esterification, and β-oxidation 83. These 
downstream factors can lead to a saturation of cytosolic fatty acid binding proteins 
(FABP) and acyl-coA binding proteins (ACBP). The uptake and subsequent activation 
of long-chain fatty acids are strongly regulated by long-chain acyl-CoAs, intracellular 
ATP and the mitochondrial carnitine transport system. 
 
Product-inhibition of long-chain acyl-CoA synthetases  
Acyl-CoA synthetases are inhibited by the product of the reaction, acyl-CoAs, and by 
a decrease in the intracellular CoA pool 84,85. Inhibition of acyl-CoA synthetase by 
accumulation of long-chain β-oxidation intermediates has been reported 86,87. 
Impaired β-oxidation in the EHHADHMUT cell line might thereby lead to a decreased 
activation of FAs and to an increased efflux. As a consequence, the actual uptake of 
palmitic acid into the EHHADHMUT cells is decreased. In vivo, this event is unlikely to 
occur, as the presence of FABPs and ACBPs sequester long-chain fatty acids and, 
thereby, eliminate their inhibiting action. In the EHHADHMUT cell line, an increase in 
acyl-CoA binding protein is shown, which in part counter-regulates in EHHADHMUT 
cells the accumulation of β-oxidiation intermediates.  
 
Regulation of cellular long-chain fatty acid uptake by the intracellular ATP level 
Activation of long-chain fatty acids is an ATP-dependent process. Lowering the 
intracellular ATP content decreases acyl-CoA synthetase activity and thereby 
activation of long-chain fatty acids to their acyl-CoAs 82,84. The EHHADHMUT cell line 
shows a decreased level of cellular ATP compared to EHHADHWT cells. This fact 
also fits the decreased uptake of palmitic acid in EHHADHMUT cells. 
 
Decreased activation of the mitochondrial carnitine transport system 
Accumulation of β-oxidation intermediates inhibits β-oxidation by product inhibition. 
This accumulation inhibits the forward reaction of CPT II and activates the reverse 
reaction for the export of the corresponding long-chain acylcarnitines. The inhibition 
of the forward reaction of CPT II leads to a saturation of cytosolic FABPs and ACBPs 
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and, thereby, to a decreased uptake of long-chain fatty acids across the cellular 
membrane.  
 
In summary, mistargeted EHHADHMUT is incorporated into MTP and impairs 
mitochondrial β-oxidation, shown by the accumulation of long-chain acylcarnitines. 
This accumulation inhibits the forward reaction of CPT II and enhances the export of 
long-chain acylcarnitines out of the cell. These cellular mechanisms downstream of 
long-chain fatty acid uptake, lead overall to a decreased uptake of long-chain fatty 
acids (Figure 26).  
 
 
Figure 26: Schematic representation of impaired mitochondrial function due to  
EHHADHMUT mistargeting. Mistargeting of EHHADHMUT into mitochondria and incorporation into MTP 
complex leads to an impaired mitochondrial β-oxidation and a decreased mitochondrial supercomplex 
assembly. Both result in reduced oxidative phosphorylation and, thereby, in a reduced intracellular 
ATP level in the EHHADHMUT cell line. This in turn decreases proximal tubular reabsorption of 
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electrolytes, amino acids, glucose and other low molecular weight compounds, leading to the 
Fanconi´s syndrome (↑↓: up/down-regulation).  
(Source: Assmann et al., Unravelling the pathomechanism of an autosomal dominant Fanconi´s 
Syndrome: a mitochondriopathy caused by mistargeting of a peroxisomal protein. Cell Rep, in 
revision) 
 
7.4.2 Formation of acetyl-CoA from β-oxidation 
Acetyl-CoA, as the endproduct of mitochondrial β-oxidation, is directly fed into the 
tricarboxylic acid cycle for further metabolisation to produce reducing equivalents 
(NADH and FADH2) and ATP. Normal mitochondrial β-oxidation of one molecule 
palmitic acid leads to the formation of 8 molecules of acetyl-CoA 88. Impaired 
mitochondrial β-oxidation leads to decreased levels of acetyl-CoA. Its flux through the 
tricarboxylic acid cycle is decreased and, as a result, less energy is produced. 
Impaired mitochondrial β-oxidation in EHHADHMUT cells was demonstrated by cell 
culture experiments with palmitic acid. Subsequent analysis showed decreased 
formation of 13C-labelled acetyl-CoA in EHHADHMUT cells. Absolute intracellular 
levels of acetyl-CoA, however, did not differ between EHHADHWT and EHHADHMUT 
cells, as shown by the measurement of unlabeled acetyl-CoA. The EHHADHMUT cell 
line appears to compensate for the decreased formation of acetyl-CoA from 
mitochondrial β-oxidation by deriving acetyl-CoA from other pathways, such as its 
generation from ketogenic amino acid (lysine, tryptophan, leucine, and isoleucine).  
 
7.4.3 Generation of ATP 
In renal proximal tubular cells, the ion gradient across the plasma membrane is a 
precondition for renal tubular reabsorption. It is generated by ATP-dependent 
sodium-potassium pump, Na+/K+-ATPase. The energy needed is generated by 
oxidative metabolism in proximal tubular cells.  
Fatty acids are the main source of energy in proximal tubules even in the presence of 
other metabolites 23,42. Gullans et al. 89 showed, that after the addition of 0.1 µM 
rotenone, the oxygen consumption and ATP content in cortical tubule suspension of 
rabbits are reduced to the same degree. This demonstrates, that ATP in renal 
proximal tubular cells is mainly supplied by oxidative phosphorylation, as addition of 
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the respiratory chain complex I inhibitor rotenone decreased the ATP level decreased 
to the same degree as oxidative phosphorylation was inhibited. In addition, the 
decrease in ATP content after the addition of rotenone correlated with reduced 
proximal tubular cell transport. Further, Beck et al. 24 showed a reduction in 
intracellular ATP level by approximately 40 % after the stimulation of sodium 
transport in isolated rabbit proximal convolute tubule for eight minutes. This drop in 
intracellular ATP after stimulation of sodium transport shows that the level of ATP is 
close to the cellular energy demand in proximal tubular cells. The continuous supply 
with ATP for proximal tubular cells is thus of great importance, as the stored ATP can 
maintain tubular transport for a few seconds only 90. The intracellular ATP levels in 
EHHADHWT cells are in good accordance with former published data on ATP levels in 
the LLC-PK1 cell line 91, isolated renal tubules 92, and Madin-Darby canine kidney 
cells 93, whereas intracellular ATP is decreased in the EHHADHMUT cell line, which is 
likely to explain the decreased transport activity observed in EHHADHMUT 
overexpressing cells 67.  
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7.5 Global proteomic analysis of the EHHADHWT and EHHADHMUT 
cell lines 
The proteomic analysis of different physiological states, e.g. wild type and mutated 
cell lines, is a common means to elucidate the molecular mechanisms underlying 
cellular processes 94. SWATH-MS™ analysis of the EHHADHWT and EHHADHMUT cell 
lines revealed significant differences in the abundance of constituents of the 
mitochondrial respiratory chain, mitochondrial and peroxisomal β-oxidation, and 
mitochondrial transporters.  
The decreased amounts of several complex I members shown by SWATH-MS™ 
analysis in EHHADHMUT-transfected cells can be explained by the decreased 
supercomplex formation, as the formation of mitochondrial supercomplexes is 
important for the stability of complex I 95-97. In these publications, mutation of 
complex III led to decreased stability of complex I and its subsequent degradation.  
SWATH-MS™ analysis also showed a down-regulation of peroxisomal 
multifunctional enzyme type 2 (D-bifunctional protein) and an up-regulation of 
peroxisomal bifunctional enzyme isoform 1 (EHHADH) and acyl-CoA binding protein 
in whole cell lysate of the EHHADHMUT cell line. Down-regulation of D-bifunctional 
protein is presumably an overexpression artefact in the EHHADHWT cell line, as due 
to the strong increase in EHHADH protein amount in peroxisomes, the cell counter-
regulates the amount of D-bifunctional protein. This effect is not as strong in the 
EHHADHMUT cell line due to the dual localization of EHHADHMUT, thereby reducing 
the effective concentration within the peroxisomes. Up-regulation of EHHADH is also 
explained by the mistargeting of mutated EHHADH into mitochondria. As EHHADH in 
EHHADHWT cell line is only localized to peroxisomes, the overexpression leads to a 
saturation of EHHADH in peroxisomes and to subsequent degradation of the protein. 
In contrast, in the EHHADHMUT cell line, EHHADH is localized to both, peroxisomes 
and mitochondria. Therefore, EHHADH overexpression in EHHADHMUT cell line is not 
as limited as in the EHHADHWT cell line. The increase in acyl-CoA binding protein in 
EHHADHMUT cell line may be explained by the accumulation of β-oxidation 
intermediates and thereby by an increased demand of acyl-CoA binding proteins for 
the sequestration of these toxic intermediates. 
In addition, mitochondrial transporters are significantly downregulated in the 
EHHADHMUT cell line. The mitochondrial dicarboxylate carrier transports malate and 
succinate out of the mitochondrium in exchange for phosphate 98, whereas the 
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ADP/ATP translocase transports ATP out of the mitochondrial matrix in exchange for 
cytosolic ADP 99. It is already known, that impaired mitochondrial β-oxidation and the 
resulting accumulation of β-oxidation intermediates inhibit these mitochondrial 
carriers 100-103. For the ADP/ATP translocase it has been reported, that long-chain 
acyl-CoAs inhibit the activity on the cytosolic and mitochondrial side of the IMM 
103,104. Ciapaite et al. 101 found that palmitoyl-CoA inhibits only the exchange of 
mitochondrial ATP against cytosolic ADP and has no effect of mitochondrial ATP 
synthesis. The inhibition of both, dicarboxylate carrier and ADP/ATP translocase, 
may thereby lead to a decreased amount ATP in EHHADHMUT cells. 
 
7.6 Effects of mistargeting of EHHADHMUT on mitochondrial 
respiration and supercomplex formation 
Mitochondrial β-oxidation and mitochondrial oxidative phosphorylation are tightly 
coupled processes, as reducing equivalents are directly fed into the respiratory chain. 
FADH2 is generated during the oxidation of long-chain acyl-CoA. The electrons from 
FADH2 enter directly the respiratory chain via the electron transfer flavoprotein (ETF). 
The electrons from the reduced ETF are then transferred onto ubiquinone, which is 
accomplished by the ETF:ubiquinone oxidoreductase, to build ubiquinol. Complex III 
reoxidized ubiquinol to ubiquinone and the electrons are transferred onto the 
respiratory chain complex. The second reducing equivalent formed during β-oxidation 
is NADH. The NAD+-dependent oxidation of L-3-hydroxyacyl-CoAs to 3-ketoacyl-CoA 
is catalyzed by L-3-hydroxyacyl-CoA dehydrogenase. NADH enters the respiratory 
chain at complex I. In addition, Sumegi et al. 105 showed binding of thiolase and L-3-
hydroxyacyl-CoA dehydrogenase to complex I, which is believed to enhance the 
efficient shuttling of NADH produced by β-oxidation to respiratory chain complex I. 
Furthermore, at low concentrations of NADH, the binding of L-3-hydroxyacyl-CoA 
dehydrogenase to complex I is abolished, indicating a specificity of this binding for 
metabolic channeling 106. The hypothesis of an immediate interaction between β-
oxidation and the respiratory chain has gained further support by the observation of a 
physical association between enzymes of mitochondrial β-oxidation and respiratory 
chain supercomplexes 107.  
The formation of supercomplexes promotes direct electron transfer, mediates 
substrate channeling, increases catalytic efficiency, sequesters reactive 
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intermediates, and stabilizes respiratory chain complexes 52. Mitochondrial 
supercomplexes consist of one complex I subunit, two complex III subunits and a 
variable number of complex IV subunits. In addition, the association of complex II 
with mitochondrial supercomplexes has been shown 108. According Schägger et al. 51 
approximately 84% of complex I is assembled into the supercomplexes I1III2, I1III2IV1, 
and I1III2IV2-4. Hence, only ~ 16 % of complex I is found in free form. In this study, the 
incorporation of EHHADHMUT into MTP led to decreased supercomplex assembly, as 
the erroneous incorporation of EHHADHMUT into MTP resulted in conformational 
changes of MTP and, thereby, reduced mitochondrial supercomplex formation by 
44% in the EHHADHMUT cell line.  
It is also known, that decreased supercomplex assembly will reduce oxidative 
phosphorylation capacity 97,109. By means of high-resolution respirometry a 
decreased oxidative phosphorylation capacity in the EHHADHMUT cell line compared 
to the EHHADHWT cell line was observed. The oxygen consumption after addition of 
palmitoylcarnitine for β-oxidation and pyruvate and glutamate for complex I showed a 
decrease in oxidative phosphorylation in EHHADHMUT of 30 % and 33 %, 
respectively. Both indicate a decreased supply of reducing equivalents from β-
oxidation and a modified tricarboxylic acid cycle. The addition of succinate can 
compensate to some extent the reduction in oxygen consumption to only 19 % in 
EHHADHMUT cells. LEAK respiration, after the addition of oligomycin, is also 
significantly reduced in EHHADHMUT cells compared to EHHADHWT cells. One likely 
explanation may be alterations in the IMM that impact its flexibility and, thereby, 
respiration. Baggetto et al. 110 showed, that a higher cholesterol level in the IMM is 
accompanied by a decreased LEAK respiration due to decreased proton 
permeability. In addition, Brand et al. 111 showed, that the amount of ADP/ATP 
translocase has an impact on LEAK respiration. A decrease in the amount of 
ADP/ATP translocase led to a decrease in the proton conductance, whereas the 
opposite applied to an increase in abundance of ADP/ATP translocase. Since the 
EHHADHMUT cell line showed indeed a decreased amount of ADP/ATP translocase, 
this might explain the decreased LEAK respiration. Further, as oxygen consumption 
by the EHHADHMUT cell line was still significantly decreased after uncoupling, it 
appears both the phosphorylation and non-phosphorylation system are affected in 
the EHHADHMUT cell line. 
 
99 
 
7.7 Development of diseases due to the mistargeting of proteins 
Mistargeting of proteins and the causal correlation with the development of a disease 
is a subject of research over the last years. The here described autosomal dominant 
form of Fanconi´s syndrome is caused by the mistargeting of the peroxisomal protein 
EHHADH into mitochondria. In the following, I will compare the Faconi´s syndrome 
with other mistargeting caused diseases. 
A first example in literature, where the mistargeting of a peroxisomal protein into 
mitochondria causes a genetic disease, was the autosomal recessive disease 
primary hyperoxaluria type 1 (PH1). Most of the patients with PH1 have a complete 
deficiency of the catalytic activity of the hepatic peroxisomal enzyme 
alanine/glyoxylate aminotransferase (AGT), however about a third of patients show 
residual enzyme activity 112. Human AGT is a homodimeric protein, which is in human 
solely located in peroxisomes and catalyzes the transamination of glyoxylate to 
glycine. The deficiency of AGT in the peroxisomes leads to the formation of oxalate 
from glyoxylate catalyzed by either lactate dehydrogenase or glycolate oxidase, 
which in the following deposit as insoluble calcium oxalate in the kidney and the 
urinary tract 113. The clinical presentations are urolithiasis and/or nephrocalcinosis 
and eventually lead to renal failure 114. Over the past years a large number of 
different enzymatic phenotypes have been identified in PH1, including loss of the 
catalytic activity of AGT, protein deficiency, aggregation of AGT in peroxisomes and 
the mistargeting of AGT into mitochondria 113. The latter takes place due to the 
combination of the polymorphism P11L and the PH1-specific point mutation G170R 
112, whereby 90 – 95 % of AGT 114 is mistargeted into mitochondria. The combined 
effects of both mutations are the generation of a weak mitochondrial targeting 
sequence by the P11L polymorphism and the inhibition of the AGT dimerization by 
the G170R point mutation 112,113. The dimerization of human AGT is very important, 
as it is shown that monomeric human AGT has a reduced catalytic acitivty 112 and is 
unstable , which leads to further rapid degradation 115. The mistargeted AGT is in 
mitochondria still catalytic active, although it is metabolically inefficient 114.  
Another example is the autosomal dominant nephrogenic diabetes insipidus (NDI), 
where the kidney fails to concentrate the urine in response to the anti-diuretic 
hormone arginine-vasopressin (AVP). AVP is produced in the pituitary and released 
in the case of hypernatremia or hypovolemia 116. AVP then binds to the membranous 
vasopressin type-2 receptor and via cAMP signalling leads to the phosphorylation of 
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AQP2 by protein kinase A (PKA) 117 and insertion of Aquaporin-2 (AQP2) into the 
luminal membrane. This autosomal dominant form of NDI is caused by a single 
nucleotide deletion (727ΔG) in one allele of Aquaporin-2 gene, which leads to a C-
terminal frame shift and thereby to an extended C-terminal tail 116. The other allele 
encoded the wild type AQP2 protein. AQP2 is known to form homotetramers in vivo 
and in vitro 117,118 .Marr et al. 116 showed after co-expression of the wild type and 
mutated AQP2 in Madin-Darby kidney cells, the formed heterotetramer of wild type 
and mutated AQP2 was erroneously located mainly to the late 
endosomes/lysosomes after treatment with forskolin, an adenylate cyclase activator. 
Thereby, Marr et al. showed that not the loss of function, but rather the mistargeting 
of the heterotetramer of wild type and mutated AQP2 to the late 
endosomes/lysosomes lead to the phenotype 116.  
Although PH1 and NDI are also caused by a mistargeting of a protein, the 
phenotypes of PH1 and NDI arises due to the absence of the protein in peroxisomes 
and apical membrane, respectively. Whereas in the here described Fanconi´s 
syndrome, the phenotype is caused by the erroneous localisation of EHHADHMUT in 
mitochondria and the following disturbance of normal mitochondrial function. Not the 
lack of the EHHADH in the peroxisomes leads to the development of the Fanconi´s 
syndrome, as an EHHADH-/- knockout mouse did not lead to a phenotype 
In addition, EHHADHMUT is still transported to the peroxisomes, as shown by means 
of immunofluorescence staining. 
To my knowledge, we showed for the first time, that not the failure, or the loss of 
function of the protein causes the disease, but rather the mistargeting of the protein 
into mitochondria and the resulting mitochondriopathy.  
  
101 
 
8 Conclusion and Outlook 
Mistargeting of EHHADHMUT into mitochondria and incorporation into MTP leads to 
disturbed mitochondrial fatty acid β-oxidation and respiratory supercomplex 
formation. Due to impaired mitochondrial β-oxidation, EHHADHMUT cells produce less 
acetyl-CoA, accumulate acylcarnitines, and take up less fatty acids. In addition, 
decreased supercomplex assembly is observed. Together they reduce oxidative 
phosphorylation capacity, leading to decreased mitochondrial energy production in 
the EHHADHMUT cell line. Ultimately, this mitochondriopathy causes decreased 
tubular reabsorption of electrolytes and low-molecular-weight proteins, resulting in 
the Fanconi´s syndrome. This decreased tubular transport capacity for the 
nonmetabolizable glucose surrogate methyl α-D-glucoside in EHHADHMUT cells 
compared to the EHHADHMUT cell line was already shown by Klootwijk and 
coworkers 67. 
Further research should aim at the analysis of intracellular long-chain acyl-CoA, as 
they exert a stronger inhibitory effect on mitochondrial and cellular transporters 
compared to long-chain acylcarnitines. In addition, the stoichiometry and abundance 
of incorporation of EHHADHMUT into MTP will be of interest, as it is shown by 
immunofluorescence analysis that not all MTP complexes are affected to the same 
extent, thus explaining the less severe accumulation of β-oxidation intermediates in 
comparison to other MTP deficiencies. In addition, the metabolic and proteomic 
analysis of urine and blood plasma specimens from affected family members will 
provide further insights into the underlying pathomechnism, as a cell culture model is 
and will remain an artificial system. Purification of MTP complex from both 
EHHADHWT and EHHADHMUT cells and determination of its activity based on 
established protocols 119-123 will provide insight into the functional consequences of 
the erroneous incorporation of EHHADHMUT into MTP. 
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